<pmc-articleset xmlns:ns0="http://www.niso.org/schemas/ali/1.0/" xmlns:ns1="http://www.w3.org/1999/xlink">
<article xml:lang="en" article-type="review-article" dtd-version="1.4">
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
<restricted-by>pmc</restricted-by>
</processing-meta>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id>
<journal-id journal-id-type="pmc-domain-id">2764</journal-id>
<journal-id journal-id-type="pmc-domain">vaccines</journal-id>
<journal-id journal-id-type="publisher-id">vaccines</journal-id>
<journal-title-group>
<journal-title>Vaccines</journal-title>
</journal-title-group>
<issn pub-type="epub">2076-393X</issn>
<publisher>
<publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmcid">PMC10057056</article-id>
<article-id pub-id-type="pmcid-ver">PMC10057056.1</article-id>
<article-id pub-id-type="pmcaid">10057056</article-id>
<article-id pub-id-type="pmcaiid">10057056</article-id>
<article-id pub-id-type="pmid">36992085</article-id>
<article-id pub-id-type="doi">10.3390/vaccines11030500</article-id>
<article-id pub-id-type="publisher-id">vaccines-11-00500</article-id>
<article-version article-version-type="pmc-version">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Recent Developments in Mpox Prevention and Treatment Options</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Malik</surname>
<given-names initials="S">Shiza</given-names>
</name>
<xref rid="af1-vaccines-11-00500" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western">
<surname>Ahmad</surname>
<given-names initials="T">Tahir</given-names>
</name>
<xref rid="af2-vaccines-11-00500" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author">
<name name-style="western">
<surname>Ahsan</surname>
<given-names initials="O">Omar</given-names>
</name>
<xref rid="af3-vaccines-11-00500" ref-type="aff">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6488-1722</contrib-id>
<name name-style="western">
<surname>Muhammad</surname>
<given-names initials="K">Khalid</given-names>
</name>
<xref rid="af4-vaccines-11-00500" ref-type="aff">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5789-4215</contrib-id>
<name name-style="western">
<surname>Waheed</surname>
<given-names initials="Y">Yasir</given-names>
</name>
<xref rid="af5-vaccines-11-00500" ref-type="aff">5</xref>
<xref rid="af6-vaccines-11-00500" ref-type="aff">6</xref>
<xref rid="c1-vaccines-11-00500" ref-type="corresp">*</xref>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="editor">
<name name-style="western">
<surname>See</surname>
<given-names initials="KC">Kay Choong</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<aff id="af1-vaccines-11-00500">
<label>1</label>Bridging Health Foundation, Rawalpindi, Punjab 46000, Pakistan</aff>
<aff id="af2-vaccines-11-00500">
<label>2</label>Industrial Biotechnology, Atta ur Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad 44000, Pakistan</aff>
<aff id="af3-vaccines-11-00500">
<label>3</label>Department of Medicine, Foundation University School of Health Sciences, Foundation University Islamabad, Islamabad 44000, Pakistan</aff>
<aff id="af4-vaccines-11-00500">
<label>4</label>Department of Biology, College of Science, UAE University, Al Ain 15551, United Arab Emirates</aff>
<aff id="af5-vaccines-11-00500">
<label>5</label>Office of Research, Innovation, and Commercialization (ORIC), Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad 44000, Pakistan</aff>
<aff id="af6-vaccines-11-00500">
<label>6</label>Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos 1401, Lebanon</aff>
<author-notes>
<corresp id="c1-vaccines-11-00500">
<label>*</label>Correspondence: <email>director.oric@szabmu.edu.pk</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>2</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2023</year>
</pub-date>
<volume>11</volume>
<issue>3</issue>
<issue-id pub-id-type="pmc-issue-id">432243</issue-id>
<elocation-id>500</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>1</month>
<year>2023</year>
</date>
<date date-type="rev-recd">
<day>15</day>
<month>2</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>2</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event event-type="pmc-release">
<date>
<day>21</day>
<month>02</month>
<year>2023</year>
</date>
</event>
<event event-type="pmc-live">
<date>
<day>30</day>
<month>03</month>
<year>2023</year>
</date>
</event>
<event event-type="pmc-last-change">
<date iso-8601-date="2024-09-14 22:25:23.413">
<day>14</day>
<month>09</month>
<year>2024</year>
</date>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023 by the authors.</copyright-statement>
<copyright-year>2023</copyright-year>
<license>
<ns0:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ns0:license_ref>
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" ns1:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<self-uri content-type="pmc-pdf" ns1:href="vaccines-11-00500.pdf" />
<abstract>
<p>Human mpox is an emerging epidemic in the world. The monkey pox virus (MPXV) belongs to the same family of zoonotic Orthopoxviridae as that of the smallpox virus and exhibits similar clinical symptomology. Information regarding its diagnostics, disease epidemiology, surveillance, preventive methods, and treatment strategies are being collated with time. The purpose of this review is to trace the recent events in the scientific platform that have defined new preventive and treatment strategies against mpox. A methodological approach has been used to gather data from the latest literature to comprehensively overview the emerging treatment options. The results portion will cover details regarding the prevention of mpox. It will also shed light on a brief description of contemporary vaccines and antiviral agents that have been evaluated for their treatment potential since the emergence of the mpox threat. These treatment options are setting the pace for controlling the widespread monkeypox infection. However, the limitations attached to these treatment strategies need to be tackled quickly to increase their efficacy so that they can be deployed on a large scale for the prevention of this epidemic becoming another pandemic in this decade.</p>
</abstract>
<kwd-group>
<kwd>MPXV</kwd>
<kwd>mpox</kwd>
<kwd>therapeutics</kwd>
<kwd>antiviral agents</kwd>
<kwd>vaccines</kwd>
<kwd>novel therapeutic</kwd>
<kwd>clinical management</kwd>
</kwd-group>
<funding-group>
<funding-statement>This research received no external funding.</funding-statement>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>pmc-status-qastatus</meta-name>
<meta-value>0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-live</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-embargo</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-status-released</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-open-access</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-olf</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-manuscript</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-legally-suppressed</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-has-pdf</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-has-supplement</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-pdf-only</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-suppress-copyright</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-is-real-version</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-is-scanned-article</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-preprint</meta-name>
<meta-value>no</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-prop-in-epmc</meta-name>
<meta-value>yes</meta-value>
</custom-meta>
<custom-meta>
<meta-name>pmc-license-ref</meta-name>
<meta-value>CC BY</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1-vaccines-11-00500">
<title>1. Introduction</title>
<p>Despite so many advancements in the field of biotechnology, the world still has to face the burden of epidemics that slowly become pandemics. The world has yet not overcome the COVID-19 pandemic, and other viral epidemics are already here, such as mpox, Dengue, and Ebola among others [<xref rid="B1-vaccines-11-00500" ref-type="bibr">1</xref>]. The mpox virus is a zoonotic double-stranded DNA virus belonging to the family of Orthopoxviridae. Some other infectious viruses of the past such as poxvirus, variola, cowpox, and vaccinia virus also belong to the same family [<xref rid="B2-vaccines-11-00500" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-11-00500" ref-type="bibr">3</xref>]. Most of these other viruses of this family have caused havoc in past decades due to their link with large-scale pandemics [<xref rid="B4-vaccines-11-00500" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-11-00500" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-11-00500" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-11-00500" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-11-00500" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-11-00500" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-11-00500" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-11-00500" ref-type="bibr">11</xref>]. Therefore, scientists are worried about the evolution of an mpox endemic to the world [<xref rid="B3-vaccines-11-00500" ref-type="bibr">3</xref>]. So far, these are limited to African countries; however, some recent outbreaks have been reported in other continents as far as America, Asia, and Europe. The situation is thus alarming for scientific and healthcare networks around the world [<xref rid="B12-vaccines-11-00500" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-11-00500" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-11-00500" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-11-00500" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-11-00500" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-11-00500" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-11-00500" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-11-00500" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-11-00500" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-11-00500" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-11-00500" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-11-00500" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-11-00500" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-11-00500" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-11-00500" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-11-00500" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-11-00500" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-11-00500" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-11-00500" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-11-00500" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-11-00500" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-11-00500" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-11-00500" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-11-00500" ref-type="bibr">35</xref>].</p>
<p>The main route of viral spread is through contact with infectious sores and scabs, sharing clothes and bedding, or through the bodily transfer of fluids [<xref rid="B35-vaccines-11-00500" ref-type="bibr">35</xref>]. The symptomology of mpox infection is similar to smallpox infection with a characteristic rash, fever, and flu-like symptoms [<xref rid="B36-vaccines-11-00500" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-11-00500" ref-type="bibr">37</xref>]. According to WHO reports, approximately 68,000 disease incidences of mpox infection have been reported in endemic and outbreak regions. Moreover, 68 deaths have been recorded since the reporting of the first case of monkeypox infection [<xref rid="B35-vaccines-11-00500" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-11-00500" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-11-00500" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-11-00500" ref-type="bibr">38</xref>]. At the time of writing this review, mpox has spread to 110 different countries of European, Asian, American, Middle Eastern, Australian, and South Asian origin [<xref rid="B35-vaccines-11-00500" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-11-00500" ref-type="bibr">36</xref>]. The prevention, diagnosis, and treatment options for mpox are being developed from previous orthopox infection management. As it has a similar nature to smallpox and variola, the potential threat of the pandemic is the prime concern of the scientific community, and therefore vigorous effort is being made to deduce the effective therapeutic options and vaccination drives against monkeypox infection to avoid another biowarfare between humans and virus in the present decade [<xref rid="B35-vaccines-11-00500" ref-type="bibr">35</xref>,<xref rid="B39-vaccines-11-00500" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-11-00500" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-11-00500" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-11-00500" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-11-00500" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-11-00500" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-11-00500" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-11-00500" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-11-00500" ref-type="bibr">47</xref>].</p>
<p>At present, the mpox is still in limited endemic form with mild and self-limiting disease symptoms [<xref rid="B48-vaccines-11-00500" ref-type="bibr">48</xref>]. Therefore, in most places, supportive care is being provided to patients, and preventive techniques are being promoted to avoid further virus spread in communities [<xref rid="B49-vaccines-11-00500" ref-type="bibr">49</xref>]. However, the scientific community is still working continuously to compose antiviral therapies and useful vaccines ahead of time to tackle any future threats possibly arising from mpox [<xref rid="B50-vaccines-11-00500" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-11-00500" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-11-00500" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-11-00500" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-11-00500" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-11-00500" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-11-00500" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-11-00500" ref-type="bibr">57</xref>]. As of now, two vaccines have gained FDA approval, namely JYNNEOS<sup>TM</sup> and ACAM200<sup>®</sup>, which belong to live replication-incompetent and replication-competent vaccinia viruses, respectively [<xref rid="B58-vaccines-11-00500" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-11-00500" ref-type="bibr">59</xref>]. Moreover, some antiviral agents such as tecovirimat, brincidofovir, and cidofovir are also being suggested for tackling mpox in severe diseased cases and immunocompromised patients [<xref rid="B58-vaccines-11-00500" ref-type="bibr">58</xref>,<xref rid="B60-vaccines-11-00500" ref-type="bibr">60</xref>]. The purpose of this article is to briefly evaluate the work carried out in the direction of prevention, treatment, and therapeutic compliance with mpox outbreaks and to discuss some of the latest technologies that are being given due consideration for future research orientation in the field of vaccinology and pharmaceuticals. Moreover, light will also be shed upon the need to carry out more research and collaborative work for preventing mpox outbreaks in non-endemic countries.</p>
</sec>
<sec sec-type="methods" id="sec2-vaccines-11-00500">
<title>2. Methodology</title>
<p>A methodological approach has been used to gather the latest data regarding the different dimensions of mpox prevention and treatment strategies, which allowed the inclusion of data from diverse, recent, and the most-cited sources of research studies.</p>
<sec id="sec2dot1-vaccines-11-00500">
<title>2.1. Data Extraction and Search Strategy</title>
<p>We researched electronic sources such as Google Scholar, Pub Med, NIH (National Library of Medicine), Scopus (Elsevier), and Web of Science. Moreover, the official websites of the WHO, CDC, UNAID, and FDA were also used to obtain the statistical results and latest updates regarding mpox treatment efforts. As the study mainly incorporates the data regarding therapeutics and vaccines against MPXV, the major research terms were “Monkeypox virus”, “mpox”, “mpox epidemic”, “therapeutics against mpox”, “antiviral agents”, “vaccines against mpox”, “vaccination strategies”, “therapies against mpox”, “novel therapeutic approaches”, and some other linked search terms.</p>
</sec>
<sec id="sec2dot2-vaccines-11-00500">
<title>2.2. Inclusion and Exclusion Criteria</title>
<p>After a thorough analysis of the dates, abstracts, titles, and journals of research publications, they were made part of this review. The process of information gathering was not limited to a few studies but rather collected from research compilations in the form of original research articles, reviews, short commentaries, case reports, and letters to the editors. Finally, the search strategy was limited to incorporating data from 2018 to 2022 to add only the most recent advances related to mpox management, especially during the latest endemic updates of 2022.</p>
</sec>
</sec>
<sec sec-type="results" id="sec3-vaccines-11-00500">
<title>3. Results</title>
<p>Extensive data are already present regarding mpox etiology, epidemiology, latest updates on its outbreaks, infection cycle, host viral interaction, and possible viral targets for treatment purposes in recent publications [<xref rid="B1-vaccines-11-00500" ref-type="bibr">1</xref>,<xref rid="B61-vaccines-11-00500" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-11-00500" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-11-00500" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-11-00500" ref-type="bibr">64</xref>]. Therefore, in this section we will only discuss the prevention strategies and treatment options, including vaccination and antiviral agents, that have come forward during outbreak months. The focus of the article remains, and readers obtain maximum information to understand therapeutic interventions against monkeypox infection.</p>
<sec id="sec3dot1-vaccines-11-00500">
<title>3.1. Monkeypox: Course of the Epidemic and Possible Reasons for Recent Decline in Cases</title>
<p>MPXVwas first reported as an infection of zoonotic origin in the DRC back in 1970. It mostly remains endemic to 11 African countries, mainly the DRC, for these past 50 years [<xref rid="B3-vaccines-11-00500" ref-type="bibr">3</xref>,<xref rid="B22-vaccines-11-00500" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-11-00500" ref-type="bibr">23</xref>]. Vulnerable cases, including children, pregnant women, and the elderly with a suppressed immune system, are more prone to develop severe conditions [<xref rid="B30-vaccines-11-00500" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-11-00500" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-11-00500" ref-type="bibr">32</xref>]. Owing to its likely similarity with smallpox infection, the smallpox vaccine can be utilized against monkeypox as directed by the WHO. A few vaccine candidates, including the smallpox vaccine, vaccine candidates, and antiviral agents reported in; tabular format in this study, are currently being employed and tested for the treatment of mpox in endemic regions [<xref rid="B33-vaccines-11-00500" ref-type="bibr">33</xref>,<xref rid="B36-vaccines-11-00500" ref-type="bibr">36</xref>].</p>
<p>The endemic nature of mpox has slowly taken the form of an epidemic due to reported cases in different far-off countries, such as the reported outbreaks in Nigeria in 2022 [<xref rid="B24-vaccines-11-00500" ref-type="bibr">24</xref>]. Similarly, some cases have been reported in the UK, back in April 2022 [<xref rid="B17-vaccines-11-00500" ref-type="bibr">17</xref>]. According to the WHO, approximately 110 countries have already reported confirmed cases of mpox; these may include the UK, Spain, Portugal, Canada, Germany, Belgium, Italy, France, the Netherlands, Sweden, the UAE, the Czech Republic, Brazil, America, and most reported in the DRC [<xref rid="B4-vaccines-11-00500" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-11-00500" ref-type="bibr">5</xref>,<xref rid="B8-vaccines-11-00500" ref-type="bibr">8</xref>,<xref rid="B21-vaccines-11-00500" ref-type="bibr">21</xref>,<xref rid="B32-vaccines-11-00500" ref-type="bibr">32</xref>,<xref rid="B37-vaccines-11-00500" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-11-00500" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-11-00500" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-11-00500" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-11-00500" ref-type="bibr">41</xref>]. However, it should be noted that the cases are pertinent to change on an everyday basis, and cases may be differently reported by the WHO and CDC by the time of this publication. Until the date, 31 January 2023, ~ 21163 confirmed cases of mpox have been reported from 29 EU/EEA countries. In the latest reports presented by the WHO, the regions of America (88.2%) and of Africa (5.7%) have reported the highest number of mpox cases. However, there is also an observed decrease in overall mpox cases, by approximately 12.7%, compared to previous months [<xref rid="B42-vaccines-11-00500" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-11-00500" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-11-00500" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-11-00500" ref-type="bibr">45</xref>].</p>
<p>The possible reason for the declining number of cases might be that the high-risk core groups of individuals have been undergoing vaccination. This scenario has generated a vaccination-elicited immunity in high-risk core groups [<xref rid="B4-vaccines-11-00500" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-11-00500" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-11-00500" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-11-00500" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-11-00500" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-11-00500" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-11-00500" ref-type="bibr">10</xref>]. Mpox cases are thus declining naturally. Moreover, the effective public health measure adoption in these endemic regions has also limited the spread of mpox infections [<xref rid="B4-vaccines-11-00500" ref-type="bibr">4</xref>,<xref rid="B7-vaccines-11-00500" ref-type="bibr">7</xref>]. An additional factor that should be noted is that mpox has neither a lifelong survival nature nor has purely the characteristic nature of sexually transmitted diseases such as HIV [<xref rid="B4-vaccines-11-00500" ref-type="bibr">4</xref>,<xref rid="B12-vaccines-11-00500" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-11-00500" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-11-00500" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-11-00500" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-11-00500" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-11-00500" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-11-00500" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-11-00500" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-11-00500" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-11-00500" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-11-00500" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-11-00500" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-11-00500" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-11-00500" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-11-00500" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-11-00500" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-11-00500" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-11-00500" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-11-00500" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-11-00500" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-11-00500" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-11-00500" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-11-00500" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-11-00500" ref-type="bibr">35</xref>]. The disease mostly remains self-limiting and resolves within 2–4 weeks of symptoms, as the host slowly develops immunity against it. Thus, it is taken as an acute infection. However, it remains still unknown whether the first time mpox elicits durable and protective immunity to protect the host from re-infection or else they required proper medication and vaccination to prevent future infections. Moreover, the nature of sexual transmission is still needed to be confirmed, since the high-risk group seems to have adopted some behavioral modifications such as limiting sexual encounters, which is suggested as the major reason behind the reduced spread of mpox [<xref rid="B60-vaccines-11-00500" ref-type="bibr">60</xref>]. Owing to these factors, there has been a natural decrease in mpox cases worldwide, though the situation keeps on changing every day [<xref rid="B37-vaccines-11-00500" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-11-00500" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-11-00500" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-11-00500" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-11-00500" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-11-00500" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-11-00500" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-11-00500" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-11-00500" ref-type="bibr">45</xref>].</p>
</sec>
<sec id="sec3dot2-vaccines-11-00500">
<title>3.2. Preventive Measures against Monkeypox</title>
<p>Whenever an infectious outbreak hits the world, the first step is to determine a prevention protocol against it. Such is the case for the mpox resurging outbreak. For now, the approved vaccine is a smallpox vaccine that has been checked against mpox and has FDA approval status against smallpox but is still limited to a specific group of personnel. Thus, further clinical trials are needed for confirmed approval against mpox [<xref rid="B62-vaccines-11-00500" ref-type="bibr">62</xref>,<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>]. Other preventive measures proposed by healthcare authorities such as the WHO and CDC are outlined in the following section [<xref rid="B34-vaccines-11-00500" ref-type="bibr">34</xref>,<xref rid="B36-vaccines-11-00500" ref-type="bibr">36</xref>,<xref rid="B47-vaccines-11-00500" ref-type="bibr">47</xref>,<xref rid="B66-vaccines-11-00500" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-11-00500" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-11-00500" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-11-00500" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-11-00500" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-11-00500" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-11-00500" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-11-00500" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-11-00500" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-11-00500" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-11-00500" ref-type="bibr">76</xref>].</p>
<list list-type="bullet">
<list-item>
<p>Avoidance of direct zoonotic contact with animals that may carry mpox, such as monkeys and squirrels, etc.</p>
</list-item>
<list-item>
<p>Avoid contact with objects that may be in touch with the infected animals outside of the infected places.</p>
</list-item>
<list-item>
<p>Avoid contact with sick individuals with suspected and confirmed mpox since the infection easily spreads through body lesions.</p>
</list-item>
<list-item>
<p>Proper sanitization and hand washing after contact with infected objects, places, and animals and use of personal protective equipment when encountering infected individuals.</p>
</list-item>
<list-item>
<p>Thorough washing and proper cooking of animal meat products.</p>
</list-item>
<list-item>
<p>Adopting careful measures during physical interaction.</p>
</list-item>
<list-item>
<p>Isolation of infected individuals to avoid infection spreading to other persons.</p>
</list-item>
<list-item>
<p>Wearing medical masks and gloves in cases of confirmed mpox.</p>
</list-item>
<list-item>
<p>Proper disinfection and cleaning of infected places and hospital floors.</p>
</list-item>
<list-item>
<p>Increase public awareness regarding risks of infection, preventive measures, and possible treatment options.</p>
</list-item>
<list-item>
<p>People with an increased risk of developing infection such as medical staff, laboratory workers, scientists, response teams, healthcare workers, and captive animals must be subjected to pre-exposure vaccination to avoid infection spread.</p>
</list-item>
<list-item>
<p>Captive animals with the infection must be separated from other animals with proper quarantine care.</p>
</list-item>
</list>
</sec>
<sec id="sec3dot3-vaccines-11-00500">
<title>3.3. Pre-Exposure Prophylaxis</title>
<p>In addition to the above-mentioned points, healthcare authorities including the Advisory Committee and Immunization Practices (ACIP) have recommended the pre- and post-prophylaxis vaccination for a specific group of people [<xref rid="B74-vaccines-11-00500" ref-type="bibr">74</xref>]. For pre-exposure prophylaxis, vaccination with the FDA-approved vaccines (ACAM2000<sup>®</sup> and JYNNEOS<sup>TM</sup>) is recommended for people working for healthcare authorities with occupations where direct exposure to orthopoxviruses is predicted [<xref rid="B72-vaccines-11-00500" ref-type="bibr">72</xref>,<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>]. These may include laboratory technicians and workers, clinical personnel involved in viral disease management, response teams against outbreaks, and vaccination and diagnostic teams, as well as scientists researching on clinical samples of mpox. Thus, proper vaccination protocols should be proposed for ensuring the safety for these personnel.</p>
</sec>
<sec id="sec3dot4-vaccines-11-00500">
<title>3.4. Post-Exposure Prophylaxis</title>
<p>PEP is recommended upon unprotected contact with the skin mucous membrane of an infected person or with their bodily fluids, saliva, lesions, oral cavity, clothing, bedding, etc. [<xref rid="B72-vaccines-11-00500" ref-type="bibr">72</xref>]. It may also be needed for people undergoing close space-sharing for long lengths (around 3 h or more) with the infected person, which may expose them to viruses through aerosol secretions and viral presence in air particles [<xref rid="B78-vaccines-11-00500" ref-type="bibr">78</xref>]. Additionally, post-exposure vaccination is only recommended by the FDA and CDC for high-degree exposures where there is a possible risk of contracting the virus but not a predictive confirmation as in the case of directly exposed persons [<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-11-00500" ref-type="bibr">78</xref>]. Additionally, the lack of protective gloves and medical masks or contact-used material without pre- and post-exposure sanitization is a condition that sensitizes and necessitates vaccination. In cases of uncertain exposure or lower exposure rates, the recommended measures are to undergo diagnosis or monitoring before PEP [<xref rid="B72-vaccines-11-00500" ref-type="bibr">72</xref>,<xref rid="B78-vaccines-11-00500" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-11-00500" ref-type="bibr">79</xref>]. Transmission takes place with prolonged interaction with an infected animal or symptomatic individuals. Thus, with informed guidance from the CDC, post-exposure vaccination should be conducted after approximately 4 days and within a period of 4–14 days to avert disease development [<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>,<xref rid="B79-vaccines-11-00500" ref-type="bibr">79</xref>]. If conducted later than the two week period, the disease onset cannot be prevented; however, the disease can only be reduced [<xref rid="B79-vaccines-11-00500" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-11-00500" ref-type="bibr">80</xref>].</p>
</sec>
<sec id="sec3dot5-vaccines-11-00500">
<title>3.5. Therapeutics and Vaccines</title>
<p>Enormous therapeutics have been proposed, with some having promising results against orthopoxvirus family members. These compounds have proven antiviral effects on smallpox treatment, but there are no confirmed results for mpox in human beings [<xref rid="B74-vaccines-11-00500" ref-type="bibr">74</xref>]. However, as the first line of treatment, these antiviral agents, vaccines, and drugs are being utilized to avert the spread of mpox until a properly approved vaccine arrives in the healthcare market [<xref rid="B80-vaccines-11-00500" ref-type="bibr">80</xref>].</p>
</sec>
<sec id="sec3dot6-vaccines-11-00500">
<title>3.6. Vaccination Efforts against MPox</title>
<p>As described earlier, it is too soon to expect a vaccine against mpox since the outbreaks have been quite recently reported in different countries; before the current outbreak, the mpox was limited to only a few endemic regions of Africa [<xref rid="B28-vaccines-11-00500" ref-type="bibr">28</xref>]. However, now that the virus is surging in different countries, scientists have increased the pace of research to deliver an effective vaccine specific against mpox along with efficacious antiviral drugs [<xref rid="B2-vaccines-11-00500" ref-type="bibr">2</xref>]. At present, smallpox vaccines which exhibit up to 85% protection are being used for mpox, which is a good line to start [<xref rid="B62-vaccines-11-00500" ref-type="bibr">62</xref>,<xref rid="B81-vaccines-11-00500" ref-type="bibr">81</xref>]. The epidemiological data indicate that most of the mpox-infected cases were those who did not receive smallpox vaccination in childhood or had never been infected with poxviruses or those who were born after the smallpox pandemic and eradication period [<xref rid="B82-vaccines-11-00500" ref-type="bibr">82</xref>]. Currently, only two smallpox vaccines have been approved for mpox: a brief report of both vaccines is discussed ahead.</p>
<p>Upon CDC recommendation, these approved vaccines are used in the form of pre-exposure and post-exposure prophylaxis for some specific groups of people as discussed before. Apart from the approved vaccines, some other vaccination trials are also going on. One such experiment was on the Dryvax vaccine and the vaccinia virus vaccine (MVA), which were checked individually and in combination to determine the immune system response. The response came in terms of the initiation of cellular and humoral immune responses [<xref rid="B60-vaccines-11-00500" ref-type="bibr">60</xref>,<xref rid="B83-vaccines-11-00500" ref-type="bibr">83</xref>]. Moreover, some experiments on animal models compared the effect of vaccination on disease symptomology. Vaccinated animals were healthier and exhibited fewer or no symptoms while the non-vaccinated animals exhibited various illness symptoms associated with MPXV infection [<xref rid="B60-vaccines-11-00500" ref-type="bibr">60</xref>,<xref rid="B84-vaccines-11-00500" ref-type="bibr">84</xref>].</p>
<p>Similarly, some animal models were checked for protein-based vaccination, and they experienced mild to severe symptoms of disease yet still survived, unlike those animals that received DNA fragments and could survive [<xref rid="B85-vaccines-11-00500" ref-type="bibr">85</xref>]. Similarly, some studies concomitantly used both DNA and protein-based vaccines and received good results in the form of lower symptom rates and disease resolution within a few days. Immune system incitation in the form of antibody production against B-cell-conserved epitopes of mpox was also observed in these animals [<xref rid="B86-vaccines-11-00500" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-11-00500" ref-type="bibr">87</xref>,<xref rid="B88-vaccines-11-00500" ref-type="bibr">88</xref>]. Moreover, experiments have also been conducted to check the impact of passive immunization by the transfer of vaccinia-neutralizing antibodies which demonstrated effective immune system responses in receiving animals [<xref rid="B34-vaccines-11-00500" ref-type="bibr">34</xref>]. All these studies need to be further checked, and confirmation on human models is the next step to officially obtain a licensed vaccine against mpox. At present, only the approved vaccination is being used for pre- and post-exposure prophylaxis in high-risk individuals. The risk attached to the immune escape, viral mutation, and other strains of orthopox viruses make it imperative to work continuously on alternative vaccines specified against mpox [<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>,<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>].</p>
</sec>
<sec id="sec3dot7-vaccines-11-00500">
<title>3.7. A Brief Account of Approved Vaccines</title>
<p>Two approved vaccines, JYNNEOS<sup>TM</sup> and ACAM2000<sup>®</sup>, are currently being utilized for pre- and post-prophylaxis in specific patients. These vaccines are not readily available and are limited to some endemic regions and most developed countries for precautionary use against mpox-reported cases. Apart from these two vaccines, another vaccine, Aventis Pasteur Smallpox Vaccine (APSV) (a replication-competent vaccinia vaccine), is authorized for emergency purposes in case the other two vaccines are not available or contradicted for application. Some characteristic features of both approved vaccines are shown in <xref rid="vaccines-11-00500-t001" ref-type="table">Table 1</xref>, and a brief account of other vaccine trials is summarized in <xref rid="vaccines-11-00500-t002" ref-type="table">Table 2</xref> below.</p>
</sec>
<sec id="sec3dot8-vaccines-11-00500">
<title>3.8. Antiviral Therapeutics against MPox</title>
<p>The smallpox viruses caused havoc back in its pandemic times and is still considered a bioweapon for its associated lethality and infectivity. Owing to the similar nature of monkeypox viruses, scientists are putting a lot of effort to propose rigorous drugs against mpox. The suggested drugs are undergoing approval stages, and some are being used for the supportive care of patients [<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>]. Problems associated with vaccination restriction compel the healthcare authorities to heavily rely on these supportive drugs and antiviral agents in case of treatment urgency. Moreover, the disease cases which already developed symptomology of mpox vaccine remain ineffective for reducing the symptoms, and thus drugs come into play. The three most common drugs that are being utilized against mpox are named Cidofovir, Brincidofovir, and Tecovirimat. A brief account of these drugs is discussed below.</p>
</sec>
<sec id="sec3dot9-vaccines-11-00500">
<title>3.9. Cidofovir (Vistide<sup>®</sup>) against MPox</title>
<p>This is a broad-spectrum antiviral agent which acts to terminate DNA polymerase-based replication in the form of 5′-diphosphorylated metabolite and thus is effective against a wide range of DNA viruses. It has proven to be efficacious against viral infections such as HIV, vaccinia, mpox, smallpox, etc. [<xref rid="B98-vaccines-11-00500" ref-type="bibr">98</xref>]. The main routes of administration include topical and intravenous administration. The best feature of this antiviral agent is that it decreases the symptomology to avert lesions formation and reduces mortality rates. It is used as a second-line therapy for severe vaccinia [<xref rid="B82-vaccines-11-00500" ref-type="bibr">82</xref>,<xref rid="B99-vaccines-11-00500" ref-type="bibr">99</xref>]. Specifically, in the case of mpox, the trials have demonstrated reversed mpox by inhibiting mpox replication (proven in vitro and in vivo experiments) [<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>]. However, it has been reported to cause nephrotoxicity during intravenous administration and thus requires probenecid and hydration and proper dose adjustment with renal functional considerations to deal with nephrotoxicity. Moreover, more clinical experimentation is required on mpox cases in humans [<xref rid="B48-vaccines-11-00500" ref-type="bibr">48</xref>].</p>
</sec>
<sec id="sec3dot10-vaccines-11-00500">
<title>3.10. Brincidofovir (Formerly CMX001) against MPox</title>
<p>Brincidofovir functions by phosphorylation to its active metabolic form “cidofovir diphosphate”. It selectively inhibits activity against orthopox DNA polymerase and thus has proven effective against DNA viruses. It is also known as a lipid conjugate of cidofovir and is considered to be a cidofovir diphosphate prodrug. Lipid acylic nucleoside phosphonate works as a phospholipid in the body and lessens lesion formation with no proven impact with coupled vaccination [<xref rid="B81-vaccines-11-00500" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-11-00500" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-11-00500" ref-type="bibr">83</xref>]. In some cases, reports demonstrated complete recovery of patients with minimal side effects. Thus, it received approval against cytomegalovirus retinitis in HIV patients and received approval for smallpox and related infections in 2021. It is preferred for rapid and widespread administration in cases of emergency outbreaks. Unlike cidofovir, it has good oral bioavailability and no reported nephrotoxicity; therefore, it is approved for oral administration [<xref rid="B82-vaccines-11-00500" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-11-00500" ref-type="bibr">83</xref>,<xref rid="B99-vaccines-11-00500" ref-type="bibr">99</xref>]. However, the liver enzymatic profile must be carefully regulated, and functional tests must be conducted for the application. Additionally, due to hyperactive drug accumulation, it not recommended for immunocompromised patients, pregnant women, and newborns [<xref rid="B43-vaccines-11-00500" ref-type="bibr">43</xref>]. Recently animal experimentation against mpox reported effective treatment, but it requires more clinical experiments for proper approval and licensure [<xref rid="B79-vaccines-11-00500" ref-type="bibr">79</xref>,<xref rid="B84-vaccines-11-00500" ref-type="bibr">84</xref>].</p>
</sec>
<sec id="sec3dot11-vaccines-11-00500">
<title>3.11. Tecovirimat (TPOXX)-(ST-246) against MPox</title>
<p>This was licensed in 2018 for smallpox and in 2022 for mpox [<xref rid="B64-vaccines-11-00500" ref-type="bibr">64</xref>]. It functions to inhibit viral egress by targeting a unique gene that produces the m37 (F13L) envelope protein required for viral maturation and release [<xref rid="B85-vaccines-11-00500" ref-type="bibr">85</xref>]. It has reported high efficacy against orthopoxvirsues by reducing viral replication pace and viral load. Moreover, it causes delayed viral infection onset and decreases lesion formation and thus causes reduced infection symptomology and mortality rates [<xref rid="B86-vaccines-11-00500" ref-type="bibr">86</xref>]. Repeated experiments have well established its safety, tolerability, and pharmacokinetic profiles. It showed concomitant immunological effects in coupled vaccination experiments. However, the issue of drug resistance development is there, and no teratogenicity has been predicted in pregnant women [<xref rid="B87-vaccines-11-00500" ref-type="bibr">87</xref>]. Specifically for mpox, it has been checked in humans but lacks randomized phase 3 trials and thus needs further experimentation [<xref rid="B88-vaccines-11-00500" ref-type="bibr">88</xref>].</p>
</sec>
<sec id="sec3dot12-vaccines-11-00500">
<title>3.12. Vaccinia Immune Globulin (VIG) against MPox</title>
<p>This was licensed in 2018 against vaccinia virus infections. It acts as an alternative to antiviral agents. Its derivatives, recombinant immunoglobulins (rVIG), are under investigation [<xref rid="B34-vaccines-11-00500" ref-type="bibr">34</xref>,<xref rid="B49-vaccines-11-00500" ref-type="bibr">49</xref>]. rVIGs work on a strategic passive immunotherapy approach. The candidate’s plasma-derived vaccinia immunoglobulins (VIG), VIGIV Cangene and VIGIV Dynport, are under investigation and are not licensed yet [<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>,<xref rid="B88-vaccines-11-00500" ref-type="bibr">88</xref>]. It has been used successfully in refractive cases. As a hyperimmune globulin, it functions to neutralize virus particles and reduces viremia and mortality rates by up to 30–40% [<xref rid="B57-vaccines-11-00500" ref-type="bibr">57</xref>,<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>,<xref rid="B89-vaccines-11-00500" ref-type="bibr">89</xref>]. Antibodies are collected from the plasma of smallpox-immune individuals to create passive immunity. It has been redistricted for application in immunodeficient individuals as it contains amounts of maltose that possibly affect glycemic conditions and insulin levels, may interfere with serological testing, needs caution for renal insufficient profiles, and increases revaccination needs [<xref rid="B43-vaccines-11-00500" ref-type="bibr">43</xref>,<xref rid="B79-vaccines-11-00500" ref-type="bibr">79</xref>,<xref rid="B84-vaccines-11-00500" ref-type="bibr">84</xref>]. There are a lack of human testing data against mpox and thus needs further investigation. Apart from these three antiviral agents, some other important drug candidates under trial against mpox are summarized in <xref rid="vaccines-11-00500-t003" ref-type="table">Table 3</xref>. Note that a detailed explanation of these trials can be traced in the referenced publications since a detailed analysis of these studies is beyond scope of this review article.</p>
</sec>
<sec>
<title>3.13. Future Directions for Antiviral Therapies against Mpox</title>
<p>As progress in the field of biotechnology increases, more effort is being put forward to propose novel therapeutic approaches against emerging infectious diseases. Knowing the scope of current targeted therapy approaches such as those based on microRNAs and silencing RNAs, there is work happening to find accurate targeted molecules against mpox [<xref rid="B3-vaccines-11-00500" ref-type="bibr">3</xref>,<xref rid="B74-vaccines-11-00500" ref-type="bibr">74</xref>]. Similarly, biomarker-based therapies are also in research annals as biomarkers offer an effective targeting and flexible drug design approach against different kind of diseases [<xref rid="B89-vaccines-11-00500" ref-type="bibr">89</xref>]. For viral diseases, the biobased approaches allow effective screening, diagnosis, prognosis, and mitigative vaccination and adaptive treatment measures [<xref rid="B80-vaccines-11-00500" ref-type="bibr">80</xref>,<xref rid="B98-vaccines-11-00500" ref-type="bibr">98</xref>]. Moreover, by integrating the in silico and bioinformatic statistical and molecular models with biomarker-based theory, more sophisticated therapies could be formulated with fewer side effects, better delivery, reduced resistance potential, and improved pharmacokinetic properties [<xref rid="B2-vaccines-11-00500" ref-type="bibr">2</xref>,<xref rid="B48-vaccines-11-00500" ref-type="bibr">48</xref>]. The next step in the development of better antivirals against infectious diseases such as mpox includes the discovery of better cellular targets, innovative drug-targeting strategies, and improved drug delivery mechanisms [<xref rid="B95-vaccines-11-00500" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-11-00500" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-11-00500" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-11-00500" ref-type="bibr">98</xref>]. Important drug targets and biobased markers tested in different studies are part of <xref rid="vaccines-11-00500-t003" ref-type="table">Table 3</xref>. Most of these biomarkers have been proposed while keeping in consideration the genomic similarities between smallpox and mpox, which sets a trace route for future therapies [<xref rid="B38-vaccines-11-00500" ref-type="bibr">38</xref>,<xref rid="B48-vaccines-11-00500" ref-type="bibr">48</xref>,<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>,<xref rid="B80-vaccines-11-00500" ref-type="bibr">80</xref>,<xref rid="B82-vaccines-11-00500" ref-type="bibr">82</xref>,<xref rid="B95-vaccines-11-00500" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-11-00500" ref-type="bibr">96</xref>,<xref rid="B99-vaccines-11-00500" ref-type="bibr">99</xref>].</p>
<p>Another important development that is predictive to develop better treatment options for mpox in the future includes nanotechnology-based therapies [<xref rid="B90-vaccines-11-00500" ref-type="bibr">90</xref>,<xref rid="B97-vaccines-11-00500" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-11-00500" ref-type="bibr">98</xref>]. Specifically, silver nanoparticles have been investigated for their proven antimicrobial properties. AGNPs are being utilized to decrease the infectivity of mpox in different studies [<xref rid="B96-vaccines-11-00500" ref-type="bibr">96</xref>]. Nanotechnology-based therapies offer novel, inexpensive, and broad-spectrum treatment options against different diseases. The basic principle is to alter the properties of present and newer antivirals at the nanoscale to improve their physiochemical features and linked pharmaceutical properties [<xref rid="B74-vaccines-11-00500" ref-type="bibr">74</xref>,<xref rid="B96-vaccines-11-00500" ref-type="bibr">96</xref>]. Another approach is the conjugation of nanoparticles with the approved drugs to improve the effectiveness, targeted delivery, and improved drug delivery to the body. Specific studies of AGNPs against mpox have exhibited their dose-dependent inhibitory effect. However, more studies are needed to prove the research implication in clinical models [<xref rid="B3-vaccines-11-00500" ref-type="bibr">3</xref>,<xref rid="B48-vaccines-11-00500" ref-type="bibr">48</xref>,<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>,<xref rid="B95-vaccines-11-00500" ref-type="bibr">95</xref>,<xref rid="B99-vaccines-11-00500" ref-type="bibr">99</xref>].</p>
</sec>
</sec>
<sec sec-type="conclusions" id="sec4-vaccines-11-00500">
<title>4. Conclusions</title>
<p>Complex and exaggerating burdens have been imposed on the healthcare system owing to the COVID-19 pandemic and converging outbreaks of various other viral infections at the same time including Ebola, Dengue, and mpox (the focus of the present study). Under these pressurized conditions, the scientific community is rigorously working to produce an effective therapy against mpox and other infectious diseases. Though there is effective work being conducted in the field of vaccination and drug design, the current developments are still considered theoretical because most of the drugs are for diseases of smallpox origin. Therefore, more effort should be kept on modern therapeutic options to specify them against mpox. There is a need to coordinate their efforts with an integrated approach with the medical industry for clinical experimentation. The recommendations from healthcare authorities have been properly outlined, and treatment recommendations and vaccination protocols have also been formulated against specific groups of the workforce and susceptible persons. Thus, a coordinated and participatory approach will be needed to educate the community and general public in awareness programs regarding mitigation, adaptation, and disease management before the epidemic of mpox becomes another pandemic of the century.</p>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p>
</fn>
</fn-group>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, S.M. and Y.W.; methodology, S.M., T.A., O.A., K.M. and Y.W.; validation, S.M., O.A., K.M.; formal analysis, S.M., T.A., O.A., K.M. and Y.W.; resources Y.W.; data curation, S.M., T.A., O.A., K.M. and Y.W.; writing—original draft preparation, S.M. writing—review and editing, S.M., K.M. and Y.W.; supervision, Y.W.; project administration, Y.W. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Institutional Review Board Statement</title>
<p>Not applicable.</p>
</notes>
<notes>
<title>Informed Consent Statement</title>
<p>Not applicable.</p>
</notes>
<notes notes-type="data-availability">
<title>Data Availability Statement</title>
<p>Not applicable.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-vaccines-11-00500">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ajmera</surname>
<given-names>K.M.</given-names>
</name>
<name name-style="western">
<surname>Goyal</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Pandit</surname>
<given-names>T.</given-names>
</name>
<name name-style="western">
<surname>Pandit</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Monkeypox–An emerging pandemic</article-title>
<source>IDCases</source>
<year>2022</year>
<volume>29</volume>
<fpage>e01587</fpage>
<pub-id pub-id-type="doi">10.1016/j.idcr.2022.e01587</pub-id>
<pub-id pub-id-type="pmid">35938150</pub-id>
<pub-id pub-id-type="pmcid">PMC9352457</pub-id>
</element-citation>
</ref>
<ref id="B2-vaccines-11-00500">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Focosi</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Novazzi</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Baj</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Maggi</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Monkeypox: An international epidemic</article-title>
<source>Rev. Med. Virol.</source>
<year>2022</year>
<volume>32</volume>
<fpage>e2392</fpage>
<pub-id pub-id-type="doi">10.1002/rmv.2392</pub-id>
<pub-id pub-id-type="pmid">36029181</pub-id>
</element-citation>
</ref>
<ref id="B3-vaccines-11-00500">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Mu</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Monkeypox: Epidemiology, pathogenesis, treatment and prevention</article-title>
<source>Signal Transduct. Target. Ther.</source>
<year>2022</year>
<volume>7</volume>
<fpage>373</fpage>
<pub-id pub-id-type="doi">10.1038/s41392-022-01215-4</pub-id>
<pub-id pub-id-type="pmid">36319633</pub-id>
<pub-id pub-id-type="pmcid">PMC9626568</pub-id>
</element-citation>
</ref>
<ref id="B4-vaccines-11-00500">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Zambrano</surname>
<given-names>P.G.</given-names>
</name>
<name name-style="western">
<surname>Acosta-España</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Moyano</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Jara</surname>
<given-names>J.B.A.</given-names>
</name>
</person-group>
<article-title>Sexually or intimately transmitted infections: A look at the current outbreak of monkeypox in 2022</article-title>
<source>Travel Med. Infect. Dis.</source>
<year>2022</year>
<volume>49</volume>
<fpage>102383</fpage>
<pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102383</pub-id>
<pub-id pub-id-type="pmid">35714856</pub-id>
<pub-id pub-id-type="pmcid">PMC9528244</pub-id>
</element-citation>
</ref>
<ref id="B5-vaccines-11-00500">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Quarleri</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Delpino</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Galvan</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Monkeypox: Considerations for the understanding and containment of the current outbreak in non-endemic countries</article-title>
<source>Geroscience</source>
<year>2022</year>
<volume>44</volume>
<fpage>2095</fpage>
<lpage>2103</lpage>
<pub-id pub-id-type="doi">10.1007/s11357-022-00611-6</pub-id>
<pub-id pub-id-type="pmid">35726117</pub-id>
<pub-id pub-id-type="pmcid">PMC9208705</pub-id>
</element-citation>
</ref>
<ref id="B6-vaccines-11-00500">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Shaheen</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Diab</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Meshref</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Shaheen</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Ramadan</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Shoib</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Is there a need to be worried about the new monkeypox virus outbreak? A brief review on the monkeypox outbreak</article-title>
<source>Ann. Med. Surg.</source>
<year>2022</year>
<volume>81</volume>
<fpage>104396</fpage>
<pub-id pub-id-type="doi">10.1016/j.amsu.2022.104396</pub-id>
<pub-id pub-id-type="pmid">36147131</pub-id>
<pub-id pub-id-type="pmcid">PMC9486661</pub-id>
</element-citation>
</ref>
<ref id="B7-vaccines-11-00500">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lansiaux</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Jain</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Laivacuma</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Reinis</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The virology of human monkeypox virus (hMPOX): A brief overview</article-title>
<source>Virus Res.</source>
<year>2022</year>
<volume>322</volume>
<fpage>198932</fpage>
<pub-id pub-id-type="doi">10.1016/j.virusres.2022.198932</pub-id>
<pub-id pub-id-type="pmid">36165924</pub-id>
<pub-id pub-id-type="pmcid">PMC9534104</pub-id>
</element-citation>
</ref>
<ref id="B8-vaccines-11-00500">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Girometti</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Byrne</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Bracchi</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Heskin</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>McOwan</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Tittle</surname>
<given-names>V.</given-names>
</name>
<name name-style="western">
<surname>Gedela</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Scott</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Patel</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Gohil</surname>
<given-names>J.</given-names>
</name>
<etal />
</person-group>
<article-title>Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: An observational analysis</article-title>
<source>Lancet Infect. Dis.</source>
<year>2022</year>
<volume>22</volume>
<fpage>1321</fpage>
<lpage>1328</lpage>
<pub-id pub-id-type="doi">10.1016/S1473-3099(22)00411-X</pub-id>
<pub-id pub-id-type="pmid">35785793</pub-id>
<pub-id pub-id-type="pmcid">PMC9534773</pub-id>
</element-citation>
</ref>
<ref id="B9-vaccines-11-00500">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Català</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Clavo-Escribano</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Riera-Monroig</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Martín-Ezquerra</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Fernandez-Gonzalez</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Revelles-Peñas</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Simon-Gozalbo</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Rodríguez-Cuadrado</surname>
<given-names>F.J.</given-names>
</name>
<name name-style="western">
<surname>Castells</surname>
<given-names>V.G.</given-names>
</name>
<name name-style="western">
<surname>de la Torre Gomar</surname>
<given-names>F.J.</given-names>
</name>
<etal />
</person-group>
<article-title>Monkeypox outbreak in Spain: Clinical and epidemiological findings in a prospective cross-sectional study of 185 cases</article-title>
<source>Br. J. Dermatol.</source>
<year>2022</year>
<volume>187</volume>
<fpage>765</fpage>
<lpage>772</lpage>
<pub-id pub-id-type="doi">10.1111/bjd.21790</pub-id>
<pub-id pub-id-type="pmid">35917191</pub-id>
</element-citation>
</ref>
<ref id="B10-vaccines-11-00500">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>De Baetselier</surname>
<given-names>I.</given-names>
</name>
<name name-style="western">
<surname>Van Dijck</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Kenyon</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Coppens</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Michiels</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>de Block</surname>
<given-names>T.</given-names>
</name>
<name name-style="western">
<surname>Smet</surname>
<given-names>H.</given-names>
</name>
<name name-style="western">
<surname>Coppens</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Vanroye</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Bugert</surname>
<given-names>J.J.</given-names>
</name>
<etal />
</person-group>
<article-title>Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium</article-title>
<source>Nat. Med.</source>
<year>2022</year>
<volume>28</volume>
<fpage>2288</fpage>
<lpage>2292</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-022-02004-w</pub-id>
<pub-id pub-id-type="pmid">35961373</pub-id>
<pub-id pub-id-type="pmcid">PMC9671802</pub-id>
</element-citation>
</ref>
<ref id="B11-vaccines-11-00500">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Bukhari</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>The truth of monkeypox outbreak: A guide for the diagnostic laboratories, health care workers and community in Pakistan</article-title>
<source>Biomedica</source>
<year>2022</year>
<volume>38</volume>
<fpage>53</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.51441/BioMedica/5-734</pub-id>
</element-citation>
</ref>
<ref id="B12-vaccines-11-00500">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Albin</surname>
<given-names>J.S.</given-names>
</name>
<name name-style="western">
<surname>Lazarus</surname>
<given-names>J.E.</given-names>
</name>
<name name-style="western">
<surname>Hysell</surname>
<given-names>K.M.</given-names>
</name>
<name name-style="western">
<surname>Rubins</surname>
<given-names>D.M.</given-names>
</name>
<name name-style="western">
<surname>Germaine</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Dugdale</surname>
<given-names>C.M.</given-names>
</name>
<name name-style="western">
<surname>Heller</surname>
<given-names>H.M.</given-names>
</name>
<name name-style="western">
<surname>Hohmann</surname>
<given-names>E.L.</given-names>
</name>
<name name-style="western">
<surname>Baugh</surname>
<given-names>J.J.</given-names>
</name>
<name name-style="western">
<surname>Shenoy</surname>
<given-names>E.S.</given-names>
</name>
</person-group>
<article-title>Development and implementation of a clinical decision support system tool for the evaluation of suspected monkeypox infection</article-title>
<source>J. Am. Med. Inform. Assoc.</source>
<year>2022</year>
<volume>29</volume>
<fpage>2124</fpage>
<lpage>2127</lpage>
<pub-id pub-id-type="doi">10.1093/jamia/ocac151</pub-id>
<pub-id pub-id-type="pmid">36036367</pub-id>
<pub-id pub-id-type="pmcid">PMC9667162</pub-id>
</element-citation>
</ref>
<ref id="B13-vaccines-11-00500">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Minhaj</surname>
<given-names>F.S.</given-names>
</name>
<name name-style="western">
<surname>Ogale</surname>
<given-names>Y.P.</given-names>
</name>
<name name-style="western">
<surname>Whitehill</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Schultz</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Foote</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Davidson</surname>
<given-names>W.</given-names>
</name>
<name name-style="western">
<surname>Hughes</surname>
<given-names>C.M.</given-names>
</name>
<name name-style="western">
<surname>Wilkins</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Bachmann</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Chatelain</surname>
<given-names>R.</given-names>
</name>
<etal />
</person-group>
<article-title>Monkeypox outbreak—Nine states, May 2022</article-title>
<source>Morb. Mortal. Wkly. Rep.</source>
<year>2022</year>
<volume>71</volume>
<fpage>764</fpage>
<pub-id pub-id-type="doi">10.15585/mmwr.mm7123e1</pub-id>
<pub-id pub-id-type="pmcid">PMC9181052</pub-id>
<pub-id pub-id-type="pmid">35679181</pub-id>
</element-citation>
</ref>
<ref id="B14-vaccines-11-00500">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lahariya</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Thakur</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Dudeja</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Monkeypox disease outbreak (2022): Epidemiology, challenges, and the way forward</article-title>
<source>Indian Pediatr.</source>
<year>2022</year>
<volume>59</volume>
<fpage>636</fpage>
<lpage>642</lpage>
<pub-id pub-id-type="doi">10.1007/s13312-022-2578-2</pub-id>
<pub-id pub-id-type="pmid">35762024</pub-id>
<pub-id pub-id-type="pmcid">PMC9419123</pub-id>
</element-citation>
</ref>
<ref id="B15-vaccines-11-00500">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Schrarstzhaupt</surname>
<given-names>I.N.</given-names>
</name>
<name name-style="western">
<surname>Fontes-Dutra</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Diaz-Quijano</surname>
<given-names>F.A.</given-names>
</name>
</person-group>
<article-title>Early estimates of the incidence trend and the reproductive number of the monkeypox epidemic in Brazil</article-title>
<source>Travel Med. Infect. Dis.</source>
<year>2022</year>
<volume>50</volume>
<fpage>102484</fpage>
<pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102484</pub-id>
<pub-id pub-id-type="pmid">36342036</pub-id>
<pub-id pub-id-type="pmcid">PMC9617678</pub-id>
</element-citation>
</ref>
<ref id="B16-vaccines-11-00500">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Yadav</surname>
<given-names>P.D.</given-names>
</name>
<name name-style="western">
<surname>Reghukumar</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Sahay</surname>
<given-names>R.R.</given-names>
</name>
<name name-style="western">
<surname>Sudeep</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Shete</surname>
<given-names>A.M.</given-names>
</name>
<name name-style="western">
<surname>Raman</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Vk</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Abraham</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Benson</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Sm</surname>
<given-names>S.</given-names>
</name>
<etal />
</person-group>
<article-title>First two cases of Monkeypox virus infection in travellers returned from UAE to India, July 2022</article-title>
<source>J. Infect.</source>
<year>2022</year>
<volume>85</volume>
<fpage>e145</fpage>
<lpage>e148</lpage>
<pub-id pub-id-type="doi">10.1016/j.jinf.2022.08.007</pub-id>
<pub-id pub-id-type="pmid">35963550</pub-id>
<pub-id pub-id-type="pmcid">PMC9556606</pub-id>
</element-citation>
</ref>
<ref id="B17-vaccines-11-00500">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Miura</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>van Ewijk</surname>
<given-names>C.E.</given-names>
</name>
<name name-style="western">
<surname>Backer</surname>
<given-names>J.A.</given-names>
</name>
<name name-style="western">
<surname>Xiridou</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Franz</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>de Coul</surname>
<given-names>E.O.</given-names>
</name>
<name name-style="western">
<surname>Brandwagt</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>van Cleef</surname>
<given-names>B.</given-names>
</name>
<name name-style="western">
<surname>van Rijckevorsel</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Swaan</surname>
<given-names>C.</given-names>
</name>
<etal />
</person-group>
<article-title>Estimated incubation period for monkeypox cases confirmed in The Netherlands, May 2022</article-title>
<source>Eurosurveillance</source>
<year>2022</year>
<volume>27</volume>
<fpage>2200448</fpage>
<pub-id pub-id-type="doi">10.2807/1560-7917.ES.2022.27.24.2200448</pub-id>
<pub-id pub-id-type="pmid">35713026</pub-id>
<pub-id pub-id-type="pmcid">PMC9205160</pub-id>
</element-citation>
</ref>
<ref id="B18-vaccines-11-00500">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Pettke</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Filén</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Widgren</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Jacks</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Glans</surname>
<given-names>H.</given-names>
</name>
<name name-style="western">
<surname>Andreasson</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Muradrasoli</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Helgesson</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Hauzenberger</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Karlberg</surname>
<given-names>M.L.</given-names>
</name>
<etal />
</person-group>
<article-title>Ten-week follow-up of monkeypox case-patient, Sweden 2022</article-title>
<source>Emerg. Infect. Dis.</source>
<year>2022</year>
<volume>28</volume>
<fpage>2074</fpage>
<lpage>2077</lpage>
<pub-id pub-id-type="doi">10.3201/eid2810.221107</pub-id>
<pub-id pub-id-type="pmid">36148930</pub-id>
<pub-id pub-id-type="pmcid">PMC9514357</pub-id>
</element-citation>
</ref>
<ref id="B19-vaccines-11-00500">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Palich</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Burrel</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Monsel</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Nouchi</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Bleibtreu</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Seang</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Bérot</surname>
<given-names>V.</given-names>
</name>
<name name-style="western">
<surname>Brin</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Gavaud</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Wakim</surname>
<given-names>Y.</given-names>
</name>
<etal />
</person-group>
<article-title>Viral loads in clinical samples of men with monkeypox virus infection: A French case series</article-title>
<source>Lancet Infect. Dis.</source>
<year>2022</year>
<volume>23</volume>
<fpage>74</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1016/S1473-3099(22)00586-2</pub-id>
<pub-id pub-id-type="pmid">36183707</pub-id>
<pub-id pub-id-type="pmcid">PMC9534074</pub-id>
</element-citation>
</ref>
<ref id="B20-vaccines-11-00500">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Mileto</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Riva</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Cutrera</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Moschese</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Mancon</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Meroni</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Giacomelli</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Bestetti</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Rizzardini</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Gismondo</surname>
<given-names>M.R.</given-names>
</name>
<etal />
</person-group>
<article-title>New challenges in human monkeypox outside Africa: A review and case report from Italy</article-title>
<source>Travel Med. Infect. Dis.</source>
<year>2022</year>
<volume>49</volume>
<fpage>102386</fpage>
<pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102386</pub-id>
<pub-id pub-id-type="pmid">35738529</pub-id>
<pub-id pub-id-type="pmcid">PMC9528171</pub-id>
</element-citation>
</ref>
<ref id="B21-vaccines-11-00500">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Selb</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Werber</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Falkenhorst</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Steffen</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Lachmann</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Ruscher</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>McFarland</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Bartel</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Hemmers</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Koppe</surname>
<given-names>U.</given-names>
</name>
<etal />
</person-group>
<article-title>A shift from travel-associated cases to autochthonous transmission with Berlin as epicentre of the monkeypox outbreak in Germany, May to June 2022</article-title>
<source>Eurosurveillance</source>
<year>2022</year>
<volume>27</volume>
<fpage>2200499</fpage>
<pub-id pub-id-type="doi">10.2807/1560-7917.ES.2022.27.27.2200499</pub-id>
<pub-id pub-id-type="pmid">35801518</pub-id>
<pub-id pub-id-type="pmcid">PMC9264732</pub-id>
</element-citation>
</ref>
<ref id="B22-vaccines-11-00500">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sukhdeo</surname>
<given-names>S.S.</given-names>
</name>
<name name-style="western">
<surname>Aldhaheri</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Lam</surname>
<given-names>W.</given-names>
</name>
<name name-style="western">
<surname>Walmsley</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>A case of human monkeypox in Canada</article-title>
<source>Can. Med. Assoc. J.</source>
<year>2022</year>
<volume>194</volume>
<fpage>E1031</fpage>
<lpage>E1035</lpage>
<pub-id pub-id-type="doi">10.1503/cmaj.220886</pub-id>
<pub-id pub-id-type="pmid">35793837</pub-id>
<pub-id pub-id-type="pmcid">PMC9481252</pub-id>
</element-citation>
</ref>
<ref id="B23-vaccines-11-00500">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Bragazzi</surname>
<given-names>N.L.</given-names>
</name>
<name name-style="western">
<surname>Kong</surname>
<given-names>J.D.</given-names>
</name>
<name name-style="western">
<surname>Mahroum</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Tsigalou</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Khamisy-Farah</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Converti</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A preliminary pooled data analysis and literature review</article-title>
<source>J. Med. Virol.</source>
<year>2022</year>
<volume>95</volume>
<fpage>e27931</fpage>
<pub-id pub-id-type="doi">10.1002/jmv.27931</pub-id>
<pub-id pub-id-type="pmid">35692117</pub-id>
</element-citation>
</ref>
<ref id="B24-vaccines-11-00500">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ilic</surname>
<given-names>I.</given-names>
</name>
<name name-style="western">
<surname>Macuzic</surname>
<given-names>I.Z.</given-names>
</name>
<name name-style="western">
<surname>Ilic</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Global outbreak of human Monkeypox in 2022: Update of epidemiology</article-title>
<source>Trop. Med. Infect. Dis.</source>
<year>2022</year>
<volume>7</volume>
<elocation-id>264</elocation-id>
<pub-id pub-id-type="doi">10.3390/tropicalmed7100264</pub-id>
<pub-id pub-id-type="pmid">36288005</pub-id>
<pub-id pub-id-type="pmcid">PMC9609983</pub-id>
</element-citation>
</ref>
<ref id="B25-vaccines-11-00500">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Waheed</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Sah</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Muhammad</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Recent developments in vaccine for viral diseases</article-title>
<source>Vaccines</source>
<year>2023</year>
<volume>11</volume>
<elocation-id>198</elocation-id>
<pub-id pub-id-type="doi">10.3390/vaccines11020198</pub-id>
<pub-id pub-id-type="pmid">36851076</pub-id>
<pub-id pub-id-type="pmcid">PMC9963468</pub-id>
</element-citation>
</ref>
<ref id="B26-vaccines-11-00500">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ophinni</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Frediansyah</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Sirinam</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Megawati</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Stoian</surname>
<given-names>A.M.</given-names>
</name>
<name name-style="western">
<surname>Enitan</surname>
<given-names>S.S.</given-names>
</name>
<name name-style="western">
<surname>Akele</surname>
<given-names>R.Y.</given-names>
</name>
<name name-style="western">
<surname>Sah</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Pongpirul</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Abdeen</surname>
<given-names>Z.</given-names>
</name>
<etal />
</person-group>
<article-title>Monkeypox: Immune response, vaccination and preventive efforts</article-title>
<source>Narra J</source>
<year>2022</year>
<volume>2</volume>
<fpage>2022</fpage>
<pub-id pub-id-type="doi">10.52225/narra.v2i3.90</pub-id>
<pub-id pub-id-type="pmcid">PMC10914130</pub-id>
<pub-id pub-id-type="pmid">38449905</pub-id>
</element-citation>
</ref>
<ref id="B27-vaccines-11-00500">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Bosworth</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Wakerley</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Houlihan</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Atabani</surname>
<given-names>S.F.</given-names>
</name>
</person-group>
<article-title>Monkeypox: An old foe, with new challenges</article-title>
<source>Infect. Prev. Pract.</source>
<year>2022</year>
<volume>4</volume>
<fpage>100229</fpage>
<pub-id pub-id-type="doi">10.1016/j.infpip.2022.100229</pub-id>
<pub-id pub-id-type="pmid">35847384</pub-id>
<pub-id pub-id-type="pmcid">PMC9283547</pub-id>
</element-citation>
</ref>
<ref id="B28-vaccines-11-00500">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Taylor</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Monkeypox: WHO to rename disease to prevent stigma</article-title>
<source>Br. Med. J. Publ. Group</source>
<year>2022</year>
<volume>377</volume>
<fpage>o1489</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.o1489</pub-id>
<pub-id pub-id-type="pmid">35710105</pub-id>
</element-citation>
</ref>
<ref id="B29-vaccines-11-00500">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Rajsri</surname>
<given-names>K.S.</given-names>
</name>
<name name-style="western">
<surname>Rao</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>A Review of Monkeypox: The New Global Health Emergency</article-title>
<source>Venereology</source>
<year>2022</year>
<volume>1</volume>
<fpage>199</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.3390/venereology1020014</pub-id>
</element-citation>
</ref>
<ref id="B30-vaccines-11-00500">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Obeid</surname>
<given-names>M.A.</given-names>
</name>
<name name-style="western">
<surname>Amawi</surname>
<given-names>H.</given-names>
</name>
<name name-style="western">
<surname>Alshehri</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Adesokan</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Monkeypox: Emerging virus of concern; antivirals and vaccines therapeutic options</article-title>
<source>Microb. Pathog.</source>
<year>2022</year>
<volume>173</volume>
<fpage>105799</fpage>
<pub-id pub-id-type="doi">10.1016/j.micpath.2022.105799</pub-id>
<pub-id pub-id-type="pmid">36182078</pub-id>
<pub-id pub-id-type="pmcid">PMC9534075</pub-id>
</element-citation>
</ref>
<ref id="B31-vaccines-11-00500">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Pastula</surname>
<given-names>D.M.</given-names>
</name>
<name name-style="western">
<surname>Tyler</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>An overview of monkeypox virus and its neuroinvasive potential</article-title>
<source>Ann. Neurol.</source>
<year>2022</year>
<volume>92</volume>
<fpage>527</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="doi">10.1002/ana.26473</pub-id>
<pub-id pub-id-type="pmid">35932225</pub-id>
</element-citation>
</ref>
<ref id="B32-vaccines-11-00500">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Patauner</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Gallo</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Durante-Mangoni</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Monkeypox infection: An update for the practicing physician: Monkeypox infection</article-title>
<source>Eur. J. Intern. Med.</source>
<year>2022</year>
<volume>104</volume>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejim.2022.08.022</pub-id>
<pub-id pub-id-type="pmid">35999095</pub-id>
<pub-id pub-id-type="pmcid">PMC9528240</pub-id>
</element-citation>
</ref>
<ref id="B33-vaccines-11-00500">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kipkorir</surname>
<given-names>V.</given-names>
</name>
<name name-style="western">
<surname>Dhali</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Srichawla</surname>
<given-names>B.</given-names>
</name>
<name name-style="western">
<surname>Kutikuppala</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Cox</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Ochieng</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Nyaanga</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Găman</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>The re-emerging monkeypox disease</article-title>
<source>Trop. Med. Int. Health</source>
<year>2022</year>
<volume>27</volume>
<fpage>961</fpage>
<lpage>969</lpage>
<pub-id pub-id-type="doi">10.1111/tmi.13821</pub-id>
<pub-id pub-id-type="pmid">36229989</pub-id>
</element-citation>
</ref>
<ref id="B34-vaccines-11-00500">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kumar</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Acharya</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Gendelman</surname>
<given-names>H.</given-names>
</name>
<name name-style="western">
<surname>Byrareddy</surname>
<given-names>S.N.</given-names>
</name>
</person-group>
<article-title>The 2022 outbreak and the pathobiology of the monkeypox virus</article-title>
<source>J. Autoimmun.</source>
<year>2022</year>
<volume>131</volume>
<fpage>102855</fpage>
<pub-id pub-id-type="doi">10.1016/j.jaut.2022.102855</pub-id>
<pub-id pub-id-type="pmid">35760647</pub-id>
<pub-id pub-id-type="pmcid">PMC9534147</pub-id>
</element-citation>
</ref>
<ref id="B35-vaccines-11-00500">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Cuérel</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Favre</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Vouga</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Pomar</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Monkeypox and Pregnancy: Latest Updates</article-title>
<source>Viruses</source>
<year>2022</year>
<volume>14</volume>
<elocation-id>2520</elocation-id>
<pub-id pub-id-type="doi">10.3390/v14112520</pub-id>
<pub-id pub-id-type="pmid">36423129</pub-id>
<pub-id pub-id-type="pmcid">PMC9693336</pub-id>
</element-citation>
</ref>
<ref id="B36-vaccines-11-00500">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Laurence</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The recent rise in sexually transmitted infections in the United States was a harbinger of the new monkeypox pandemic</article-title>
<source>AIDS Patient Care STDS</source>
<year>2022</year>
<volume>36</volume>
<fpage>333</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1089/apc.2022.29009.com</pub-id>
<pub-id pub-id-type="pmid">35947858</pub-id>
</element-citation>
</ref>
<ref id="B37-vaccines-11-00500">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Beer</surname>
<given-names>E.M.</given-names>
</name>
<name name-style="western">
<surname>Rao</surname>
<given-names>V.B.</given-names>
</name>
</person-group>
<article-title>A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy</article-title>
<source>PLoS Negl. Trop. Dis.</source>
<year>2019</year>
<volume>13</volume>
<elocation-id>e0007791</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pntd.0007791</pub-id>
<pub-id pub-id-type="pmid">31618206</pub-id>
<pub-id pub-id-type="pmcid">PMC6816577</pub-id>
</element-citation>
</ref>
<ref id="B38-vaccines-11-00500">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Webb</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Rigby</surname>
<given-names>I.</given-names>
</name>
<name name-style="western">
<surname>Michelen</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Dagens</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Cheng</surname>
<given-names>V.</given-names>
</name>
<name name-style="western">
<surname>Rojek</surname>
<given-names>A.M.</given-names>
</name>
<name name-style="western">
<surname>Dahmash</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Khader</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Gedela</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Norton</surname>
<given-names>A.</given-names>
</name>
<etal />
</person-group>
<article-title>Availability, scope and quality of monkeypox clinical management guidelines globally: A systematic review</article-title>
<source>BMJ Glob. Health</source>
<year>2022</year>
<volume>7</volume>
<fpage>e009838</fpage>
<pub-id pub-id-type="doi">10.1136/bmjgh-2022-009838</pub-id>
<pub-id pub-id-type="pmcid">PMC9472169</pub-id>
<pub-id pub-id-type="pmid">35973747</pub-id>
</element-citation>
</ref>
<ref id="B39-vaccines-11-00500">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Shuvo</surname>
<given-names>P.A.</given-names>
</name>
<name name-style="western">
<surname>Roy</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Dhawan</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Chopra</surname>
<given-names>H.</given-names>
</name>
<name name-style="western">
<surname>Emran</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Recent outbreak of monkeypox: Overview of signs, symptoms, preventive measures, and guideline for supportive management</article-title>
<source>Int. J. Surg.</source>
<year>2022</year>
<volume>105</volume>
<fpage>106877</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106877</pub-id>
<pub-id pub-id-type="pmid">36067960</pub-id>
<pub-id pub-id-type="pmcid">PMC9528169</pub-id>
</element-citation>
</ref>
<ref id="B40-vaccines-11-00500">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Siegrist</surname>
<given-names>E.A.</given-names>
</name>
<name name-style="western">
<surname>Sassine</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Antivirals with activity against monkeypox: A clinically oriented review</article-title>
<source>Clin. Infect. Dis.</source>
<year>2022</year>
<volume>76</volume>
<fpage>155</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1093/cid/ciac622</pub-id>
<pub-id pub-id-type="pmcid">PMC9825831</pub-id>
<pub-id pub-id-type="pmid">35904001</pub-id>
</element-citation>
</ref>
<ref id="B41-vaccines-11-00500">
<label>41.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group>
<source>Vaccines and Immunization for Monkeypox: Interim Guidance, 24 August 2022</source>
<publisher-name>World Health Organization</publisher-name>
<publisher-loc>Geneva, Switzerland</publisher-loc>
<year>2022</year>
</element-citation>
</ref>
<ref id="B42-vaccines-11-00500">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Moyo</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Musuka</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Murewanhema</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Moyo</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Dzinamarira</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Monkeypox outbreak: A perspective on Africa’s diagnostic and containment capacity</article-title>
<source>Int. J. Infect. Dis.</source>
<year>2022</year>
<volume>123</volume>
<fpage>127</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijid.2022.08.016</pub-id>
<pub-id pub-id-type="pmid">36007687</pub-id>
<pub-id pub-id-type="pmcid">PMC9534167</pub-id>
</element-citation>
</ref>
<ref id="B43-vaccines-11-00500">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Altindis</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Puca</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Shapo</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Diagnosis of monkeypox virus–An overview</article-title>
<source>Travel Med. Infect. Dis.</source>
<year>2022</year>
<volume>50</volume>
<fpage>102459</fpage>
<pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102459</pub-id>
<pub-id pub-id-type="pmid">36109000</pub-id>
<pub-id pub-id-type="pmcid">PMC9534096</pub-id>
</element-citation>
</ref>
<ref id="B44-vaccines-11-00500">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Jezek</surname>
<given-names>Z.</given-names>
</name>
<name name-style="western">
<surname>Szczeniowski</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Paluku</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Mutombo</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Grab</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Human monkeypox: Confusion with chickenpox</article-title>
<source>Acta Trop.</source>
<year>1988</year>
<volume>45</volume>
<fpage>297</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="pmid">2907258</pub-id>
</element-citation>
</ref>
<ref id="B45-vaccines-11-00500">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Upadhayay</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Arthur</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Soni</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Yadav</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Navik</surname>
<given-names>U.</given-names>
</name>
<name name-style="western">
<surname>Singh</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Gurjeet Singh</surname>
<given-names>T.</given-names>
</name>
<name name-style="western">
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Monkeypox infection: The past, present, and future</article-title>
<source>Int. Immunopharmacol.</source>
<year>2022</year>
<volume>113</volume>
<fpage>109382</fpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2022.109382</pub-id>
<pub-id pub-id-type="pmid">36330915</pub-id>
<pub-id pub-id-type="pmcid">PMC9617593</pub-id>
</element-citation>
</ref>
<ref id="B46-vaccines-11-00500">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Poland</surname>
<given-names>G.A.</given-names>
</name>
<name name-style="western">
<surname>Kennedy</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Tosh</surname>
<given-names>P.K.</given-names>
</name>
</person-group>
<article-title>Prevention of monkeypox with vaccines: A rapid review</article-title>
<source>Lancet Infect. Dis.</source>
<year>2022</year>
<volume>22</volume>
<fpage>e349</fpage>
<lpage>e358</lpage>
<pub-id pub-id-type="doi">10.1016/S1473-3099(22)00574-6</pub-id>
<pub-id pub-id-type="pmid">36116460</pub-id>
<pub-id pub-id-type="pmcid">PMC9628950</pub-id>
</element-citation>
</ref>
<ref id="B47-vaccines-11-00500">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chakraborty</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Mohapatra</surname>
<given-names>R.K.</given-names>
</name>
<name name-style="western">
<surname>Chandran</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Alagawany</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Sv</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Islam</surname>
<given-names>M.A.</given-names>
</name>
<name name-style="western">
<surname>Chakraborty</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Dhama</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Monkeypox vaccines and vaccination strategies: Current knowledge and advances. An update-Correspondence</article-title>
<source>Int. J. Surg.</source>
<year>2022</year>
<volume>105</volume>
<fpage>106869</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106869</pub-id>
<pub-id pub-id-type="pmid">36049620</pub-id>
<pub-id pub-id-type="pmcid">PMC9533893</pub-id>
</element-citation>
</ref>
<ref id="B48-vaccines-11-00500">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Thakur</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>MonkeyPox2022Tweets: A Large-Scale Twitter Dataset on the 2022 Monkeypox Outbreak, Findings from Analysis of Tweets, and Open Research Questions</article-title>
<source>Infect. Dis. Rep.</source>
<year>2022</year>
<volume>14</volume>
<fpage>855</fpage>
<lpage>883</lpage>
<pub-id pub-id-type="doi">10.3390/idr14060087</pub-id>
<pub-id pub-id-type="pmid">36412745</pub-id>
<pub-id pub-id-type="pmcid">PMC9680479</pub-id>
</element-citation>
</ref>
<ref id="B49-vaccines-11-00500">
<label>49.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kozlov</surname>
<given-names>M.</given-names>
</name>
</person-group>
<source>Can a Smallpox Drug Treat Monkeypox? What Scientists Know</source>
<publisher-name>Nature Portfolio Heidelberger Platz 3</publisher-name>
<publisher-loc>Berlin, Germany</publisher-loc>
<year>2022</year>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-022-02245-2</pub-id>
<pub-id pub-id-type="pmid">36008714</pub-id>
</element-citation>
</ref>
<ref id="B50-vaccines-11-00500">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Pastula</surname>
<given-names>D.M.</given-names>
</name>
<name name-style="western">
<surname>Copeland</surname>
<given-names>M.J.</given-names>
</name>
<name name-style="western">
<surname>Hannan</surname>
<given-names>M.C.</given-names>
</name>
<name name-style="western">
<surname>Rapaka</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Kitani</surname>
<given-names>T.</given-names>
</name>
<name name-style="western">
<surname>Kleiner</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Showler</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Yuen</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Ferriman</surname>
<given-names>E.M.</given-names>
</name>
<name name-style="western">
<surname>House</surname>
<given-names>J.</given-names>
</name>
<etal />
</person-group>
<article-title>Two cases of monkeypox-associated encephalomyelitis—Colorado and the District of Columbia, July–August 2022</article-title>
<source>Morb. Mortal. Wkly. Rep.</source>
<year>2022</year>
<volume>71</volume>
<fpage>1212</fpage>
<lpage>1215</lpage>
<pub-id pub-id-type="doi">10.15585/mmwr.mm7138e1</pub-id>
<pub-id pub-id-type="pmcid">PMC9531567</pub-id>
<pub-id pub-id-type="pmid">36136957</pub-id>
</element-citation>
</ref>
<ref id="B51-vaccines-11-00500">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sherwat</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Brooks</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Birnkrant</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Kim</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Tecovirimat and the treatment of monkeypox—Past, present, and future considerations</article-title>
<source>N. Engl. J. Med.</source>
<year>2022</year>
<volume>387</volume>
<fpage>579</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMp2210125</pub-id>
<pub-id pub-id-type="pmid">35921403</pub-id>
</element-citation>
</ref>
<ref id="B52-vaccines-11-00500">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Chakraborty</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Chandran</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Mohapatra</surname>
<given-names>R.K.</given-names>
</name>
<name name-style="western">
<surname>Alagawany</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>El-Shall</surname>
<given-names>N.A.</given-names>
</name>
<name name-style="western">
<surname>Sharma</surname>
<given-names>A.K.</given-names>
</name>
<name name-style="western">
<surname>Chakraborty</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Dhama</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Clinical management, antiviral drugs and immunotherapeutics for treating monkeypox. An update on current knowledge and futuristic prospects</article-title>
<source>Int. J. Surg.</source>
<year>2022</year>
<volume>105</volume>
<fpage>106847</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106847</pub-id>
<pub-id pub-id-type="pmid">35995352</pub-id>
<pub-id pub-id-type="pmcid">PMC9533875</pub-id>
</element-citation>
</ref>
<ref id="B53-vaccines-11-00500">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Mukherjee</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Roy</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Singh</surname>
<given-names>V.</given-names>
</name>
<name name-style="western">
<surname>Gopinath</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Pokhrel</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Jaiswal</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Monkeypox as an emerging global health threat during the COVID-19 time</article-title>
<source>Ann. Med. Surg.</source>
<year>2022</year>
<volume>79</volume>
<fpage>2022</fpage>
<pub-id pub-id-type="doi">10.1016/j.amsu.2022.104075</pub-id>
<pub-id pub-id-type="pmcid">PMC9225920</pub-id>
<pub-id pub-id-type="pmid">35774117</pub-id>
</element-citation>
</ref>
<ref id="B54-vaccines-11-00500">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Mailhe</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Beaumont</surname>
<given-names>A.-L.</given-names>
</name>
<name name-style="western">
<surname>Thy</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Le Pluart</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Perrineau</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Houhou-Fidouh</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Deconinck</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Bertin</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Ferré</surname>
<given-names>V.M.</given-names>
</name>
<name name-style="western">
<surname>Cortier</surname>
<given-names>M.</given-names>
</name>
<etal />
</person-group>
<article-title>Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: An observational cohort study</article-title>
<source>Clin. Microbiol. Infect.</source>
<year>2022</year>
<volume>29</volume>
<fpage>233</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmi.2022.08.012</pub-id>
<pub-id pub-id-type="pmid">36028090</pub-id>
<pub-id pub-id-type="pmcid">PMC9533921</pub-id>
</element-citation>
</ref>
<ref id="B55-vaccines-11-00500">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kherabi</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Nguyen</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Batteux</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Launay</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Re: ‘clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection’ by Mailhe et al</article-title>
<source>Clin. Microbiol. Infect.</source>
<year>2022</year>
<volume>29</volume>
<fpage>269</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmi.2022.10.010</pub-id>
<pub-id pub-id-type="pmid">36243350</pub-id>
<pub-id pub-id-type="pmcid">PMC9554265</pub-id>
</element-citation>
</ref>
<ref id="B56-vaccines-11-00500">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Guarner</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>del Rio</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Malani</surname>
<given-names>P.N.</given-names>
</name>
</person-group>
<article-title>Monkeypox in 2022—What clinicians need to know</article-title>
<source>J. Am. Med. Assoc.</source>
<year>2022</year>
<volume>328</volume>
<fpage>139</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2022.10802</pub-id>
<pub-id pub-id-type="pmid">35696257</pub-id>
</element-citation>
</ref>
<ref id="B57-vaccines-11-00500">
<label>57.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name name-style="western">
<surname>Moore</surname>
<given-names>M.J.</given-names>
</name>
<name name-style="western">
<surname>Rathish</surname>
<given-names>B.</given-names>
</name>
<name name-style="western">
<surname>Zahra</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Monkeypox</article-title>
<source>StatPearls [Internet]</source>
<publisher-name>StatPearls Publishing</publisher-name>
<publisher-loc>Tampa, FL, USA</publisher-loc>
<year>2022</year>
</element-citation>
</ref>
<ref id="B58-vaccines-11-00500">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lulli</surname>
<given-names>L.G.</given-names>
</name>
<name name-style="western">
<surname>Baldassarre</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Mucci</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Arcangeli</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Prevention, Risk Exposure, and Knowledge of Monkeypox in Occupational Settings: A Scoping Review</article-title>
<source>Trop. Med. Infect. Dis.</source>
<year>2022</year>
<volume>7</volume>
<elocation-id>276</elocation-id>
<pub-id pub-id-type="doi">10.3390/tropicalmed7100276</pub-id>
<pub-id pub-id-type="pmid">36288017</pub-id>
<pub-id pub-id-type="pmcid">PMC9608671</pub-id>
</element-citation>
</ref>
<ref id="B59-vaccines-11-00500">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hemati</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Farhadkhani</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Sanami</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Mohammadi-Moghadam</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>A review on insights and lessons from COVID-19 to the prevent of monkeypox pandemic</article-title>
<source>Travel Med. Infect. Dis.</source>
<year>2022</year>
<volume>50</volume>
<fpage>102441</fpage>
<pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102441</pub-id>
<pub-id pub-id-type="pmid">36084881</pub-id>
<pub-id pub-id-type="pmcid">PMC9446553</pub-id>
</element-citation>
</ref>
<ref id="B60-vaccines-11-00500">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Rizk</surname>
<given-names>J.G.</given-names>
</name>
<name name-style="western">
<surname>Lippi</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Henry</surname>
<given-names>B.</given-names>
</name>
<name name-style="western">
<surname>Forthal</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Rizk</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Prevention and treatment of monkeypox</article-title>
<source>Drugs</source>
<year>2022</year>
<volume>82</volume>
<fpage>957</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="doi">10.1007/s40265-022-01742-y</pub-id>
<pub-id pub-id-type="pmid">35763248</pub-id>
<pub-id pub-id-type="pmcid">PMC9244487</pub-id>
</element-citation>
</ref>
<ref id="B61-vaccines-11-00500">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Rao</surname>
<given-names>A.K.</given-names>
</name>
<name name-style="western">
<surname>Petersen</surname>
<given-names>B.W.</given-names>
</name>
<name name-style="western">
<surname>Whitehill</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Razeq</surname>
<given-names>J.H.</given-names>
</name>
<name name-style="western">
<surname>Isaacs</surname>
<given-names>S.N.</given-names>
</name>
<name name-style="western">
<surname>Merchlinsky</surname>
<given-names>M.J.</given-names>
</name>
<name name-style="western">
<surname>Campos-Outcalt</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Morgan</surname>
<given-names>R.L.</given-names>
</name>
<name name-style="western">
<surname>Damon</surname>
<given-names>I.</given-names>
</name>
<name name-style="western">
<surname>Sánchez</surname>
<given-names>P.J.</given-names>
</name>
<etal />
</person-group>
<article-title>Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices—United States 2022</article-title>
<source>Morb. Mortal. Wkly. Rep.</source>
<year>2022</year>
<volume>71</volume>
<fpage>734</fpage>
<pub-id pub-id-type="doi">10.15585/mmwr.mm7122e1</pub-id>
<pub-id pub-id-type="pmcid">PMC9169520</pub-id>
<pub-id pub-id-type="pmid">35653347</pub-id>
</element-citation>
</ref>
<ref id="B62-vaccines-11-00500">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Thy</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Peiffer-Smadja</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Mailhe</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Kramer</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Ferré</surname>
<given-names>V.M.</given-names>
</name>
<name name-style="western">
<surname>Houhou</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Tarhini</surname>
<given-names>H.</given-names>
</name>
<name name-style="western">
<surname>Bertin</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Beaumont</surname>
<given-names>A.L.</given-names>
</name>
<name name-style="western">
<surname>Garé</surname>
<given-names>M.</given-names>
</name>
<etal />
</person-group>
<article-title>Breakthrough infections after post-exposure vaccination against Monkeypox</article-title>
<source>N. Engl. J. Med.</source>
<year>2022</year>
<volume>387</volume>
<fpage>2477</fpage>
<lpage>2479</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMc2211944</pub-id>
<pub-id pub-id-type="pmid">36477495</pub-id>
</element-citation>
</ref>
<ref id="B63-vaccines-11-00500">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Dashraath</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Nielsen-Saines</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Mattar</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Musso</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Tambyah</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Baud</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Guidelines for pregnant individuals with monkeypox virus exposure</article-title>
<source>Lancet</source>
<year>2022</year>
<volume>400</volume>
<fpage>21</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(22)01063-7</pub-id>
<pub-id pub-id-type="pmid">35750071</pub-id>
<pub-id pub-id-type="pmcid">PMC9534144</pub-id>
</element-citation>
</ref>
<ref id="B64-vaccines-11-00500">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>O’Shea</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Interim guidance for prevention and treatment of monkeypox in persons with HIV infection—United States, August 2022</article-title>
<source>MMWR Morb. Mortal. Wkly. Rep.</source>
<year>2022</year>
<volume>71</volume>
<fpage>2022</fpage>
<pub-id pub-id-type="doi">10.15585/mmwr.mm7132e4</pub-id>
<pub-id pub-id-type="pmcid">PMC9400540</pub-id>
<pub-id pub-id-type="pmid">35951495</pub-id>
</element-citation>
</ref>
<ref id="B65-vaccines-11-00500">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Turner</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Mandia</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Keltner</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Haynes</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Faestel</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Mease</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Monkeypox in patient immunized with ACAM2000 smallpox vaccine during 2022 outbreak</article-title>
<source>Emerg. Infect. Dis.</source>
<year>2022</year>
<volume>28</volume>
<fpage>2336</fpage>
<pub-id pub-id-type="doi">10.3201/eid2811.221215</pub-id>
<pub-id pub-id-type="pmid">36104166</pub-id>
<pub-id pub-id-type="pmcid">PMC9622228</pub-id>
</element-citation>
</ref>
<ref id="B66-vaccines-11-00500">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Stittelaar</surname>
<given-names>K.J.</given-names>
</name>
<name name-style="western">
<surname>Neyts</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Naesens</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>van Amerongen</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>van Lavieren</surname>
<given-names>R.F.</given-names>
</name>
<name name-style="western">
<surname>Holý</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>De Clercq</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Niesters</surname>
<given-names>H.G.M.</given-names>
</name>
<name name-style="western">
<surname>Fries</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Maas</surname>
<given-names>C.</given-names>
</name>
<etal />
</person-group>
<article-title>Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection</article-title>
<source>Nature</source>
<year>2006</year>
<volume>439</volume>
<fpage>745</fpage>
<lpage>748</lpage>
<pub-id pub-id-type="doi">10.1038/nature04295</pub-id>
<pub-id pub-id-type="pmid">16341204</pub-id>
</element-citation>
</ref>
<ref id="B67-vaccines-11-00500">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ulloque-Badaracco</surname>
<given-names>J.R.</given-names>
</name>
<name name-style="western">
<surname>Alarcón-Braga</surname>
<given-names>E.A.</given-names>
</name>
<name name-style="western">
<surname>Hernandez-Bustamante</surname>
<given-names>E.A.</given-names>
</name>
<name name-style="western">
<surname>Al-Kassab-Córdova</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Benites-Zapata</surname>
<given-names>V.A.</given-names>
</name>
<name name-style="western">
<surname>Bonilla-Aldana</surname>
<given-names>D.K.</given-names>
</name>
<name name-style="western">
<surname>Rodriguez-Morales</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Acceptance towards Monkeypox Vaccination: A Systematic Review and Meta-Analysis</article-title>
<source>Pathogens</source>
<year>2022</year>
<volume>11</volume>
<elocation-id>1248</elocation-id>
<pub-id pub-id-type="doi">10.3390/pathogens11111248</pub-id>
<pub-id pub-id-type="pmid">36364999</pub-id>
<pub-id pub-id-type="pmcid">PMC9697127</pub-id>
</element-citation>
</ref>
<ref id="B68-vaccines-11-00500">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lozano</surname>
<given-names>J.M.</given-names>
</name>
<name name-style="western">
<surname>Muller</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Monkeypox: Potential vaccine development strategies</article-title>
<source>Trends Pharmacol. Sci.</source>
<year>2022</year>
<volume>44</volume>
<fpage>15</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2022.10.005</pub-id>
<pub-id pub-id-type="pmid">36563658</pub-id>
<pub-id pub-id-type="pmcid">PMC9730257</pub-id>
</element-citation>
</ref>
<ref id="B69-vaccines-11-00500">
<label>69.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name name-style="western">
<surname>Vaccinated</surname>
<given-names>W.S.G.</given-names>
</name>
</person-group>
<source>Special Edition: Monkeypox Information &amp; Vaccines</source>
<publisher-name>Gender &amp; Sexuality Services, University of Northern Iowa</publisher-name>
<publisher-loc>Cedar Falls, IA, USA</publisher-loc>
<year>2022</year>
</element-citation>
</ref>
<ref id="B70-vaccines-11-00500">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Gruber</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>Current status of monkeypox vaccines</article-title>
<source>NPJ Vaccines</source>
<year>2022</year>
<volume>7</volume>
<fpage>94</fpage>
<pub-id pub-id-type="doi">10.1038/s41541-022-00527-4</pub-id>
<pub-id pub-id-type="pmid">35977979</pub-id>
<pub-id pub-id-type="pmcid">PMC9385639</pub-id>
</element-citation>
</ref>
<ref id="B71-vaccines-11-00500">
<label>71.</label>
<element-citation publication-type="gov">
<person-group person-group-type="author">
<name name-style="western">
<surname>Agreement</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Monkeypox Vaccination Program Provider Agreement</article-title>
<comment>Available online: <ext-link ns1:href="https://stacks.cdc.gov/view/cdc/121243" ext-link-type="uri">https://stacks.cdc.gov/view/cdc/121243</ext-link>
</comment>
<date-in-citation content-type="access-date" iso-8601-date="2023-01-17">(accessed on 17 January 2023)</date-in-citation>
</element-citation>
</ref>
<ref id="B72-vaccines-11-00500">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Mahase</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Monkeypox: Fractional vaccine doses will be piloted as new treatment trial launches</article-title>
<source>Br. Med. J. Publ. Group</source>
<year>2022</year>
<volume>378</volume>
<fpage>o2080</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.o2080</pub-id>
<pub-id pub-id-type="pmid">35998923</pub-id>
</element-citation>
</ref>
<ref id="B73-vaccines-11-00500">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Sah</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Humayun</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Baig</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Farooq</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Hussain</surname>
<given-names>H.G.</given-names>
</name>
<name name-style="western">
<surname>Shahid</surname>
<given-names>M.U.</given-names>
</name>
<name name-style="western">
<surname>Cheema</surname>
<given-names>H.A.</given-names>
</name>
<name name-style="western">
<surname>Chandran</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Yatoo</surname>
<given-names>M.I.</given-names>
</name>
<name name-style="western">
<surname>Sharma</surname>
<given-names>A.K.</given-names>
</name>
<etal />
</person-group>
<article-title>FDA’s authorized ‘JYNNEOS’ vaccine for counteracting monkeypox global public health emergency; an update–Correspondence</article-title>
<source>Int. J. Surg.</source>
<year>2022</year>
<volume>107</volume>
<fpage>106971</fpage>
<pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106971</pub-id>
<pub-id pub-id-type="pmid">36330988</pub-id>
<pub-id pub-id-type="pmcid">PMC9617681</pub-id>
</element-citation>
</ref>
<ref id="B74-vaccines-11-00500">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Meo</surname>
<given-names>S.A.</given-names>
</name>
<name name-style="western">
<surname>Al-Masri</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Klonoff</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Alshahrani</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Al-Khlaiwi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications and Adverse Effects of JYNNEOS and ACAM2000 Monkeypox Vaccines</article-title>
<source>Vaccines</source>
<year>2022</year>
<volume>10</volume>
<elocation-id>1971</elocation-id>
<pub-id pub-id-type="doi">10.3390/vaccines10111971</pub-id>
<pub-id pub-id-type="pmid">36423066</pub-id>
<pub-id pub-id-type="pmcid">PMC9698380</pub-id>
</element-citation>
</ref>
<ref id="B75-vaccines-11-00500">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ansari</surname>
<given-names>Z.</given-names>
</name>
<name name-style="western">
<surname>Ramzan</surname>
<given-names>H.</given-names>
</name>
<name name-style="western">
<surname>Shakeel</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Is there a need of monkeypox vaccine amidst the hesitancy of COVID-19 immunization in Pakistan?</article-title>
<source>Ann. Med. Surg.</source>
<year>2022</year>
<volume>81</volume>
<fpage>104391</fpage>
<pub-id pub-id-type="doi">10.1016/j.amsu.2022.104391</pub-id>
<pub-id pub-id-type="pmcid">PMC9395223</pub-id>
<pub-id pub-id-type="pmid">36035599</pub-id>
</element-citation>
</ref>
<ref id="B76-vaccines-11-00500">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ajman</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Alenezi</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Alhasan</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Saddik</surname>
<given-names>B.</given-names>
</name>
<name name-style="western">
<surname>Alhaboob</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Altawil</surname>
<given-names>E.S.</given-names>
</name>
<name name-style="western">
<surname>Alshahrani</surname>
<given-names>F.</given-names>
</name>
<name name-style="western">
<surname>Alrabiaah</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Alaraj</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Alkriadees</surname>
<given-names>K.</given-names>
</name>
<etal />
</person-group>
<article-title>Healthcare workers’ worries and Monkeypox vaccine advocacy during the first month of the WHO Monkeypox alert: Cross-sectional survey in Saudi Arabia</article-title>
<source>Vaccines</source>
<year>2022</year>
<volume>10</volume>
<fpage>1408</fpage>
<pub-id pub-id-type="pmid">36146486</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines10091408</pub-id>
<pub-id pub-id-type="pmcid">PMC9503291</pub-id>
</element-citation>
</ref>
<ref id="B77-vaccines-11-00500">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Payne</surname>
<given-names>A.B.</given-names>
</name>
</person-group>
<article-title>Incidence of monkeypox among unvaccinated persons compared with persons receiving ≥1 JYNNEOS vaccine dose—32 US jurisdictions, July 31–September 3, 2022</article-title>
<source>MMWR Morb. Mortal. Wkly. Rep.</source>
<year>2022</year>
<volume>71</volume>
<fpage>2022</fpage>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7140e3</pub-id>
<pub-id pub-id-type="pmcid">PMC9541026</pub-id>
<pub-id pub-id-type="pmid">36201401</pub-id>
</element-citation>
</ref>
<ref id="B78-vaccines-11-00500">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Islam</surname>
<given-names>M.R.</given-names>
</name>
<name name-style="western">
<surname>Hossain</surname>
<given-names>M.J.</given-names>
</name>
<name name-style="western">
<surname>Roy</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Hasan</surname>
<given-names>A.H.M.N.</given-names>
</name>
<name name-style="western">
<surname>Rahman</surname>
<given-names>M.A.</given-names>
</name>
<name name-style="western">
<surname>Shahriar</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Bhuiyan</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks</article-title>
<source>Health Sci. Rep.</source>
<year>2022</year>
<volume>5</volume>
<fpage>e798</fpage>
<pub-id pub-id-type="doi">10.1002/hsr2.798</pub-id>
<pub-id pub-id-type="pmid">36032515</pub-id>
<pub-id pub-id-type="pmcid">PMC9399446</pub-id>
</element-citation>
</ref>
<ref id="B79-vaccines-11-00500">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>See</surname>
<given-names>K.C.</given-names>
</name>
</person-group>
<article-title>Vaccination for monkeypox virus infection in humans: A review of key considerations</article-title>
<source>Vaccines</source>
<year>2022</year>
<volume>10</volume>
<elocation-id>1342</elocation-id>
<pub-id pub-id-type="doi">10.3390/vaccines10081342</pub-id>
<pub-id pub-id-type="pmid">36016230</pub-id>
<pub-id pub-id-type="pmcid">PMC9413102</pub-id>
</element-citation>
</ref>
<ref id="B80-vaccines-11-00500">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Raccagni</surname>
<given-names>A.R.</given-names>
</name>
<name name-style="western">
<surname>Candela</surname>
<given-names>C.</given-names>
</name>
<name name-style="western">
<surname>Bruzzesi</surname>
<given-names>E.</given-names>
</name>
<name name-style="western">
<surname>Mileto</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Canetti</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Rizzo</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Castagna</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Nozza</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Real-life use of cidofovir for the treatment of severe monkeypox cases</article-title>
<source>J. Med. Virol.</source>
<year>2022</year>
<volume>95</volume>
<fpage>e28218</fpage>
<pub-id pub-id-type="doi">10.1002/jmv.28218</pub-id>
<pub-id pub-id-type="pmid">36229902</pub-id>
</element-citation>
</ref>
<ref id="B81-vaccines-11-00500">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kuroda</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Shimizu</surname>
<given-names>T.</given-names>
</name>
<name name-style="western">
<surname>Hirano</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Ishikane</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Kataoka</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Lack of clinical evidence of antiviral therapy for human monkeypox: A scoping review</article-title>
<source>J. Infect. Chemother.</source>
<year>2022</year>
<volume>29</volume>
<fpage>228</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="doi">10.1016/j.jiac.2022.10.009</pub-id>
<pub-id pub-id-type="pmid">36283609</pub-id>
<pub-id pub-id-type="pmcid">PMC9598785</pub-id>
</element-citation>
</ref>
<ref id="B82-vaccines-11-00500">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Hutson</surname>
<given-names>C.L.</given-names>
</name>
<name name-style="western">
<surname>Kondas</surname>
<given-names>A.V.</given-names>
</name>
<name name-style="western">
<surname>Mauldin</surname>
<given-names>M.R.</given-names>
</name>
<name name-style="western">
<surname>Doty</surname>
<given-names>J.B.</given-names>
</name>
<name name-style="western">
<surname>Grossi</surname>
<given-names>I.M.</given-names>
</name>
<name name-style="western">
<surname>Morgan</surname>
<given-names>C.N.</given-names>
</name>
<name name-style="western">
<surname>Ostergaard</surname>
<given-names>S.D.</given-names>
</name>
<name name-style="western">
<surname>Hughes</surname>
<given-names>C.M.</given-names>
</name>
<name name-style="western">
<surname>Nakazawa</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Kling</surname>
<given-names>C.</given-names>
</name>
<etal />
</person-group>
<article-title>Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model</article-title>
<source>mSphere</source>
<year>2021</year>
<volume>6</volume>
<fpage>e00927-20</fpage>
<pub-id pub-id-type="doi">10.1128/mSphere.00927-20</pub-id>
<pub-id pub-id-type="pmid">33536322</pub-id>
<pub-id pub-id-type="pmcid">PMC7860987</pub-id>
</element-citation>
</ref>
<ref id="B83-vaccines-11-00500">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>McCarthy</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>Therapeutic strategies to address monkeypox</article-title>
<source>Expert Rev. Anti-Infect. Ther.</source>
<year>2022</year>
<volume>20</volume>
<fpage>1249</fpage>
<lpage>1252</lpage>
<pub-id pub-id-type="doi">10.1080/14787210.2022.2113058</pub-id>
<pub-id pub-id-type="pmid">35953443</pub-id>
<pub-id pub-id-type="pmcid">PMC9491133</pub-id>
</element-citation>
</ref>
<ref id="B84-vaccines-11-00500">
<label>84.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name name-style="western">
<surname>Ramalingam</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Amaechi</surname>
<given-names>B.T.</given-names>
</name>
</person-group>
<article-title>Phytochemicals: Their Therapeutic Potential Against Dental Caries</article-title>
<source>Computational Techniques for Dental Image Analysis</source>
<publisher-name>IGI Global</publisher-name>
<publisher-loc>Hershey, PA, USA</publisher-loc>
<year>2019</year>
<fpage>238</fpage>
<lpage>275</lpage>
</element-citation>
</ref>
<ref id="B85-vaccines-11-00500">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Khalil</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Samara</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>O’Brien</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Ladhani</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Call for a unified approach to Monkeypox infection in pregnancy: Lessons from the COVID-19 pandemic</article-title>
<source>Nat. Commun.</source>
<year>2022</year>
<volume>13</volume>
<fpage>5038</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-022-32638-w</pub-id>
<pub-id pub-id-type="pmid">36028491</pub-id>
<pub-id pub-id-type="pmcid">PMC9412782</pub-id>
</element-citation>
</ref>
<ref id="B86-vaccines-11-00500">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Desai</surname>
<given-names>A.N.</given-names>
</name>
<name name-style="western">
<surname>Thompson</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Neumeister</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Arutyunova</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Trigg</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Cohen</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Compassionate use of tecovirimat for the treatment of monkeypox infection</article-title>
<source>J. Am. Med. Assoc.</source>
<year>2022</year>
<volume>328</volume>
<fpage>1348</fpage>
<lpage>1350</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2022.15336</pub-id>
<pub-id pub-id-type="pmcid">PMC9396467</pub-id>
<pub-id pub-id-type="pmid">35994281</pub-id>
</element-citation>
</ref>
<ref id="B87-vaccines-11-00500">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Warner</surname>
<given-names>B.M.</given-names>
</name>
<name name-style="western">
<surname>Klassen</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Sloan</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Deschambault</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Soule</surname>
<given-names>G.</given-names>
</name>
<name name-style="western">
<surname>Banadyga</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
<name name-style="western">
<surname>Strong</surname>
<given-names>J.E.</given-names>
</name>
<name name-style="western">
<surname>Kobasa</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Safronetz</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>In vitro and in vivo efficacy of Tecovirimat against a recently emerged 2022 Monkeypox virus isolate</article-title>
<source>Sci. Transl. Med.</source>
<year>2022</year>
<volume>14</volume>
<fpage>eade7646</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.ade7646</pub-id>
<pub-id pub-id-type="pmid">36318038</pub-id>
</element-citation>
</ref>
<ref id="B88-vaccines-11-00500">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>O’Laughlin</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Tobolowsky</surname>
<given-names>F.A.</given-names>
</name>
<name name-style="western">
<surname>Elmor</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Overton</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>O’Connor</surname>
<given-names>S.M.</given-names>
</name>
<name name-style="western">
<surname>Damon</surname>
<given-names>I.K.</given-names>
</name>
<name name-style="western">
<surname>Petersen</surname>
<given-names>B.W.</given-names>
</name>
<name name-style="western">
<surname>Rao</surname>
<given-names>A.K.</given-names>
</name>
<name name-style="western">
<surname>Chatham-Stephens</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Yu</surname>
<given-names>P.</given-names>
</name>
<etal />
</person-group>
<article-title>Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol—United States, May–August 2022</article-title>
<source>MMWR Morb. Mortal. Wkly. Rep.</source>
<year>2022</year>
<volume>71</volume>
<comment>Available online: <ext-link ns1:href="https://stacks.cdc.gov/view/cdc/121112" ext-link-type="uri">https://stacks.cdc.gov/view/cdc/121112</ext-link>
</comment>
<date-in-citation content-type="access-date" iso-8601-date="2023-01-18">(accessed on 18 January 2023)</date-in-citation>
<pub-id pub-id-type="doi">10.15585/mmwr.mm7137e1</pub-id>
<pub-id pub-id-type="pmid">36107794</pub-id>
<pub-id pub-id-type="pmcid">PMC9484807</pub-id>
</element-citation>
</ref>
<ref id="B89-vaccines-11-00500">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kar</surname>
<given-names>P.P.</given-names>
</name>
<name name-style="western">
<surname>Rath</surname>
<given-names>B.</given-names>
</name>
<name name-style="western">
<surname>Ramani</surname>
<given-names>Y.</given-names>
</name>
<name name-style="western">
<surname>Maharana</surname>
<given-names>C.S.</given-names>
</name>
</person-group>
<article-title>Amelioration of Cyclophosphamide induced immunosupression by the hydro-alcoholic extract of Gymnema sylvestre leaves in albino rats</article-title>
<source>Biomed. Pharmacol. J.</source>
<year>2019</year>
<volume>12</volume>
<fpage>251</fpage>
<lpage>258</lpage>
</element-citation>
</ref>
<ref id="B90-vaccines-11-00500">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lai</surname>
<given-names>C.-C.</given-names>
</name>
<name name-style="western">
<surname>Hsu</surname>
<given-names>C.-K.</given-names>
</name>
<name name-style="western">
<surname>Yen</surname>
<given-names>M.-Y.</given-names>
</name>
<name name-style="western">
<surname>Lee</surname>
<given-names>P.-I.</given-names>
</name>
<name name-style="western">
<surname>Ko</surname>
<given-names>W.-C.</given-names>
</name>
<name name-style="western">
<surname>Hsueh</surname>
<given-names>P.-R.</given-names>
</name>
</person-group>
<article-title>Monkeypox: An emerging global threat during the COVID-19 pandemic</article-title>
<source>J. Microbiol. Immunol. Infect.</source>
<year>2022</year>
<volume>55</volume>
<fpage>787</fpage>
<lpage>794</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmii.2022.07.004</pub-id>
<pub-id pub-id-type="pmid">35970757</pub-id>
<pub-id pub-id-type="pmcid">PMC9352646</pub-id>
</element-citation>
</ref>
<ref id="B91-vaccines-11-00500">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Johri</surname>
<given-names>N.</given-names>
</name>
<name name-style="western">
<surname>Kumar</surname>
<given-names>D.</given-names>
</name>
<name name-style="western">
<surname>Nagar</surname>
<given-names>P.</given-names>
</name>
<name name-style="western">
<surname>Maurya</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Vengat</surname>
<given-names>M.</given-names>
</name>
<name name-style="western">
<surname>Jain</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Clinical manifestations of human monkeypox infection and implications for outbreak strategy</article-title>
<source>Health Sci. Rev.</source>
<year>2022</year>
<volume>5</volume>
<fpage>100055</fpage>
<pub-id pub-id-type="doi">10.1016/j.hsr.2022.100055</pub-id>
<pub-id pub-id-type="pmcid">PMC9535997</pub-id>
<pub-id pub-id-type="pmid">36254190</pub-id>
</element-citation>
</ref>
<ref id="B92-vaccines-11-00500">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kozlov</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Monkeypox in Africa: The science the world ignored</article-title>
<source>Nature</source>
<year>2022</year>
<volume>607</volume>
<fpage>17</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1038/d41586-022-01686-z</pub-id>
<pub-id pub-id-type="pmid">35739391</pub-id>
</element-citation>
</ref>
<ref id="B93-vaccines-11-00500">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Huang</surname>
<given-names>Y.A.</given-names>
</name>
<name name-style="western">
<surname>Howard-Jones</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Durrani</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name name-style="western">
<surname>Williams</surname>
<given-names>P.C.M.</given-names>
</name>
</person-group>
<article-title>Monkeypox: A clinical update for paediatricians</article-title>
<source>J. Paediatr. Child Health</source>
<year>2022</year>
<volume>58</volume>
<fpage>1532</fpage>
<lpage>1538</lpage>
<pub-id pub-id-type="doi">10.1111/jpc.16171</pub-id>
<pub-id pub-id-type="pmid">35979896</pub-id>
<pub-id pub-id-type="pmcid">PMC9545589</pub-id>
</element-citation>
</ref>
<ref id="B94-vaccines-11-00500">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lum</surname>
<given-names>F.M.</given-names>
</name>
<name name-style="western">
<surname>Torres-Ruesta</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Tay</surname>
<given-names>M.Z.</given-names>
</name>
<name name-style="western">
<surname>Lin</surname>
<given-names>R.T.</given-names>
</name>
<name name-style="western">
<surname>Lye</surname>
<given-names>D.C.</given-names>
</name>
<name name-style="western">
<surname>Rénia</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Ng</surname>
<given-names>L.F.</given-names>
</name>
</person-group>
<article-title>Monkeypox: Disease epidemiology, host immunity and clinical interventions</article-title>
<source>Nat. Rev. Immunol.</source>
<year>2022</year>
<volume>22</volume>
<fpage>597</fpage>
<lpage>613</lpage>
<pub-id pub-id-type="doi">10.1038/s41577-022-00775-4</pub-id>
<pub-id pub-id-type="pmid">36064780</pub-id>
<pub-id pub-id-type="pmcid">PMC9443635</pub-id>
</element-citation>
</ref>
<ref id="B95-vaccines-11-00500">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Goyal</surname>
<given-names>L.</given-names>
</name>
<name name-style="western">
<surname>Ajmera</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Pandit</surname>
<given-names>R.</given-names>
</name>
<name name-style="western">
<surname>Pandit</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Prevention and treatment of monkeypox: A step-by-step guide for healthcare professionals and general population</article-title>
<source>Cureus</source>
<year>2022</year>
<volume>14</volume>
<fpage>2022</fpage>
<pub-id pub-id-type="doi">10.7759/cureus.28230</pub-id>
<pub-id pub-id-type="pmcid">PMC9393027</pub-id>
<pub-id pub-id-type="pmid">36017480</pub-id>
</element-citation>
</ref>
<ref id="B96-vaccines-11-00500">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Kupferschmidt</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Monkeypox vaccination plans take shape amid questions</article-title>
<source>Science</source>
<year>2022</year>
<volume>376</volume>
<fpage>1142</fpage>
<lpage>1143</lpage>
<pub-id pub-id-type="doi">10.1126/science.add3743</pub-id>
<pub-id pub-id-type="pmid">35679422</pub-id>
</element-citation>
</ref>
<ref id="B97-vaccines-11-00500">
<label>97.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name name-style="western">
<surname>Lal</surname>
<given-names>H.M.</given-names>
</name>
<name name-style="western">
<surname>Uthaman</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Thomas</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Silver Nanoparticle as an Effective Antiviral Agent</article-title>
<source>Polymer Nanocomposites Based on Silver Nanoparticles</source>
<publisher-name>Springer</publisher-name>
<publisher-loc>Berlin/Heidelberg, Germany</publisher-loc>
<year>2021</year>
<fpage>247</fpage>
<lpage>265</lpage>
</element-citation>
</ref>
<ref id="B98-vaccines-11-00500">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Al Jurdi</surname>
<given-names>A.</given-names>
</name>
<name name-style="western">
<surname>Kotton</surname>
<given-names>C.N.</given-names>
</name>
</person-group>
<article-title>Monkeypox in Transplant Recipients: No Breaks Between Outbreaks</article-title>
<source>Transplantation</source>
<year>2022</year>
<volume>106</volume>
<fpage>e512</fpage>
<lpage>e513</lpage>
<pub-id pub-id-type="doi">10.1097/TP.0000000000004337</pub-id>
<pub-id pub-id-type="pmid">35973036</pub-id>
</element-citation>
</ref>
<ref id="B99-vaccines-11-00500">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western">
<surname>Malik</surname>
<given-names>S.</given-names>
</name>
<name name-style="western">
<surname>Muhammad</surname>
<given-names>K.</given-names>
</name>
<name name-style="western">
<surname>Waheed</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Nanotechnology: A revoulation in modern industry</article-title>
<source>Molecules</source>
<year>2023</year>
<volume>28</volume>
<elocation-id>661</elocation-id>
<pub-id pub-id-type="doi">10.3390/molecules28020661</pub-id>
<pub-id pub-id-type="pmid">36677717</pub-id>
<pub-id pub-id-type="pmcid">PMC9865684</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap position="float" id="vaccines-11-00500-t001" orientation="portrait">
<object-id pub-id-type="pii">vaccines-11-00500-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>A brief comparison of characteristics of approved mpox vaccines.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IMVAMUNE/JYNNEOS<sup>TM</sup> Vaccine</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ACAM2000<sup>®</sup> Vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccines based on live attenuated and replication deficient mechanism of action [<xref rid="B38-vaccines-11-00500" ref-type="bibr">38</xref>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Belongs to the category of live vaccinia virus [<xref rid="B38-vaccines-11-00500" ref-type="bibr">38</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No reaction at the inclusion site, no risk of inadvertent or autoinoculation reactions, and low risk of advertent transmission or vertical transmission due to replication incompetence [<xref rid="B49-vaccines-11-00500" ref-type="bibr">49</xref>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cutaneous reaction at the inoculation site. Risk of inadvertent and autoinoculation and progressive vaccinia and eczema development especially in immunocompromised. Additionally, the transmission risk for the replicative potential [<xref rid="B49-vaccines-11-00500" ref-type="bibr">49</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replication incompetent strains of vaccinia Ankara-Bavarian Nordic (MVA-BN strain) are used [<xref rid="B38-vaccines-11-00500" ref-type="bibr">38</xref>,<xref rid="B49-vaccines-11-00500" ref-type="bibr">49</xref>,<xref rid="B58-vaccines-11-00500" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-11-00500" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-11-00500" ref-type="bibr">60</xref>,<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The vaccinia virus strains are kept replication competent [<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It is referred to as a “third-generation vaccine” [<xref rid="B58-vaccines-11-00500" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-11-00500" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-11-00500" ref-type="bibr">60</xref>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It is referred to as a “second-generation vaccine” [<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Can be used even in immunodeficient persons [<xref rid="B58-vaccines-11-00500" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-11-00500" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-11-00500" ref-type="bibr">60</xref>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced symptoms but possible side effects in immunocompromised people [<xref rid="B89-vaccines-11-00500" ref-type="bibr">89</xref>,<xref rid="B90-vaccines-11-00500" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-11-00500" ref-type="bibr">91</xref>,<xref rid="B92-vaccines-11-00500" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-11-00500" ref-type="bibr">93</xref>,<xref rid="B94-vaccines-11-00500" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-11-00500" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-11-00500" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-11-00500" ref-type="bibr">97</xref>].</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not for the general population but for pre- and post-exposure prophylaxis.</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not available for the public even in endemic regions.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Freeze-dried/subcutaneous</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Storage Lyophilized/scarification</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Authorized by EMA in 2013 and FDA in 2019 for the general population [<xref rid="B83-vaccines-11-00500" ref-type="bibr">83</xref>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Received FDA licensure in 2007 for a specific group of populations [<xref rid="B97-vaccines-11-00500" ref-type="bibr">97</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved for smallpox with the name IMVANEX<sup>®</sup>, used for 18 years or older; 85% effective against mpox [<xref rid="B81-vaccines-11-00500" ref-type="bibr">81</xref>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It replaced orthopoxvirus vaccine Dryvax [<xref rid="B89-vaccines-11-00500" ref-type="bibr">89</xref>]</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It is produced by modified vaccinia Ankara-Bavarian Nordic (MVA-BN) strains that are grown in cell culture of primary chicken embryo fibroblast (CEF) cells.</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It is manufactured by allowing NYCBH strain culturation in Vero cells.</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap position="float" id="vaccines-11-00500-t002" orientation="portrait">
<object-id pub-id-type="pii">vaccines-11-00500-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Two other vaccines candidates in trials against mpox.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Replicating Potential</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Storage/Route</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Regulatory Status</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dryvax<sup>®</sup>
</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Freeze-dried/scarification</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Discontinued manufacturing in the 1980s. Replaced with the new vaccine</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC16m8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lyophilized, scarification</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Licensed for use in Japan</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap position="float" id="vaccines-11-00500-t003" orientation="portrait">
<object-id pub-id-type="pii">vaccines-11-00500-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>Summary of some anti-viral agents against mpox.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sr.no.</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Categories</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Formulations under Investigation</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Importance Interventions</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA polymerase inhibitors</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit DNA replication</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleoside phosphonates<break />Cidofovir and Brincidofovir<break />HPMA and adenosine N1 oxide (ANO)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trials, No effective tests from compounds such as acyclovir, brovavir, lobucavir, didanosine, ddC, or d4C, etc.</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-vaccines-11-00500" ref-type="bibr">82</xref>,<xref rid="B98-vaccines-11-00500" ref-type="bibr">98</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inosine monophosphate (IMP) dehydrogenase inhibitors</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of viral replication</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ribavirin and Tiazofurin</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trials</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>,<xref rid="B80-vaccines-11-00500" ref-type="bibr">80</xref>,<xref rid="B90-vaccines-11-00500" ref-type="bibr">90</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-Adenosylhomocysteine (SAH) hydrolase inhibitors</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit viral replication</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3-deazaneplanocin A (C3-NPC A) and carbocyclic-3-deazaadenosine (C-CA3-ADO)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High sensitivity to different viruses, potent antiviral effects exhibited in vivo tests, limited or no side effects</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-vaccines-11-00500" ref-type="bibr">98</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA and protein synthesis inhibitors</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replication inhibition</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33T57/Methisazone (Marboran<sup>®</sup>)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not licensed yet, 30–40% efficacy, may promote side effects such as nausea and vomiting</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>,<xref rid="B81-vaccines-11-00500" ref-type="bibr">81</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleoside analogues inhibitor</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit the DNA replication process</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nioch-14</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Easy to produce strong antiviral activity against many orthopoxviruses</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-vaccines-11-00500" ref-type="bibr">91</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination therapy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination therapy<break />Live attenuated viruses +antiviral drug</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACAM2000 and Tecovirimat combination therapy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo animal testing models (Cynomolgus macaques and Rhesus macaques)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>,<xref rid="B91-vaccines-11-00500" ref-type="bibr">91</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">combination therapy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleotide analogs</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cidofovir and Elstree-RIVM</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo animal testing models (Cynomolgus macaques)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-vaccines-11-00500" ref-type="bibr">58</xref>,<xref rid="B77-vaccines-11-00500" ref-type="bibr">77</xref>,<xref rid="B83-vaccines-11-00500" ref-type="bibr">83</xref>,<xref rid="B91-vaccines-11-00500" ref-type="bibr">91</xref>,<xref rid="B98-vaccines-11-00500" ref-type="bibr">98</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral agent</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleotide analog and a DNA polymerase inhibitor<break />Modified cidofovir compound; inhibits DNA polymerase</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMX001</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo animal testing models (Rabbit)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-vaccines-11-00500" ref-type="bibr">81</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">combination therapy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">vaccinia virus + F13L gene inhibition</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACAM2000 and Tecovirimat</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo animal testing (Cynomolgus macaques)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-vaccines-11-00500" ref-type="bibr">59</xref>,<xref rid="B81-vaccines-11-00500" ref-type="bibr">81</xref>,<xref rid="B90-vaccines-11-00500" ref-type="bibr">90</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral agent</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits release of intracellular virus</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ST246</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo animal testing (<italic toggle="yes">Cynomys ludovicianus</italic>)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-vaccines-11-00500" ref-type="bibr">59</xref>,<xref rid="B81-vaccines-11-00500" ref-type="bibr">81</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunomodulators</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immune system modulation</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(A27L, VACV A33R, L1R, and B5R) Subunit vaccines and recombinant vaccine</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vivo animal testing</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-vaccines-11-00500" ref-type="bibr">34</xref>,<xref rid="B81-vaccines-11-00500" ref-type="bibr">81</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral agents</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of viral replication</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA interference (siE8-d and siA6-a), Methisazone (Marboran), Hydroxyurea, DFBA</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro (cultured LLC-MK2 cells).<break />Limited activities.</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-vaccines-11-00500" ref-type="bibr">49</xref>,<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>,<xref rid="B88-vaccines-11-00500" ref-type="bibr">88</xref>]</td>
</tr>
<tr>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bio-based markers</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted antiviral agents</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Actin beta, Deoxythymidylate kinase, Annexin A1, Ubiquitin, Fi colin 2, Interferon-gamma, Interleukin 15, GTP cyclohydrolase I feedback regulator Membrane associated ring-CH-type finger 1, MNAT1 component of CDK Activating kinase, Makorin ring finger protein 3Specific peptidase 9 X-linked Retinoid X receptor alpha, IL-12A, Major histocompatibility complex, STAT3, Calpastatin cyclin dependent kinase 5, WASP actin nucleation promoting factor, SH3 domain binding protein 4, T cell receptor beta variable 20/OR9-2, TNF, Tyrosinase, Uroplakin 3B.</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing trials</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-vaccines-11-00500" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-11-00500" ref-type="bibr">3</xref>,<xref rid="B34-vaccines-11-00500" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-11-00500" ref-type="bibr">35</xref>,<xref rid="B38-vaccines-11-00500" ref-type="bibr">38</xref>,<xref rid="B48-vaccines-11-00500" ref-type="bibr">48</xref>,<xref rid="B64-vaccines-11-00500" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-11-00500" ref-type="bibr">65</xref>,<xref rid="B85-vaccines-11-00500" ref-type="bibr">85</xref>,<xref rid="B92-vaccines-11-00500" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-11-00500" ref-type="bibr">93</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>